

Edgar Filing: Symmetry Medical Inc. - Form 10-K

Symmetry Medical Inc.  
Form 10-K  
March 08, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934  
For the Fiscal Year Ended January 1, 2011  
Commission File Number 001-32374

SYMMETRY MEDICAL INC.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State of Incorporation)

35-1996126  
(I.R.S. Employer  
Identification No.)

3724 North State Road 15  
Warsaw, Indiana 46582  
(Address of Principal Executive Offices) (Zip Code)  
(574) 268-2252  
(Registrant's Telephone Number, Including Area Code)  
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:	Name of Each Exchange on Which Registered:
Common Stock, Par Value \$0.001 Per Share	New York Stock Exchange

Securities registered pursuant to section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  
Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Edgar Filing: Symmetry Medical Inc. - Form 10-K

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No   
The aggregate market value of voting stock of Symmetry Medical Inc. held by non-affiliates of the Registrant as of July 3, 2010, based on the closing price was \$10.39, as reported by the New York Stock Exchange: Approximately \$373.5 million.

The number of shares outstanding of the registrant's common stock as of March 4, 2011 was 36,345,292.

**DOCUMENTS INCORPORATED BY REFERENCE**

Certain information is incorporated into Part III of this report by reference to the Registrant's 2011 Proxy Statement to be filed with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year covered by this Form 10-K.

---

TABLE OF CONTENTS  
 SYMMETRY MEDICAL INC.

TABLE OF CONTENTS

PART I	
Item 1. Business	3
Item 1A. Risk Factors	13
Item 1B. Unresolved Staff Comments	24
Item 2. Properties	24
Item 3. Legal Proceedings	25
Item 4. (Removed and Reserved)	25
PART II	
Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	25
Item 6. Selected Financial Data	27
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations	28
Item 7A. Quantitative and Qualitative Disclosures About Market Risks	37
Item 8. Financial Statements and Supplementary Data	39
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	62
Item 9A. Controls and Procedures	62
Item 9B. Other Information	62
PART III	
Item 10. Directors, Executive Officers and Corporate Governance	63
Item 11. Executive Compensation	63
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	63
Item 13. Certain Relationships and Related Transactions and Director Independence	63

Item 14.		
Principal Accounting Fees and Services		63

PART IV

Item 15.		
Exhibits, Financial Statement Schedules		64
Signatures		66

#### Cautionary Note Regarding Forward-Looking Statements

Throughout this Annual Report on Form 10-K, or in other reports or registration statements filed from time to time with the Securities and Exchange Commission under the Securities Exchange Act of 1934, or under the Securities Act of 1933, as well as in documents we incorporate by reference or in press releases or oral statements made by our officers or representatives, we may make statements that express our opinions, expectations, or projections regarding future events or future results, in contrast with statements that reflect historical facts. These predictive statements, which we generally precede or accompany by such typical conditional words such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," "potential," or "expect," or by the words "may," "will," "could," or "should," and similar expressions or terminology are intended to operate as "forward-looking statements" of the kind permitted by the Private Securities Litigation Reform Act of 1995. That legislation protects such predictive statements by creating a "safe harbor" from liability in the event that a particular prediction does not turn out as anticipated.

Forward-looking statements convey our current expectations or forecast future events. While we always intend to express our best judgment when we make statements about what we believe will occur in the future, and although we base these statements on assumptions that we believe to be reasonable when made, these forward-looking statements are not a guarantee of performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many uncertainties and other variable circumstances, many of which are outside of our control, that could cause our actual results and experience to differ materially from those we thought would occur.

We also refer you to and believe that you should carefully read the portion of this report described in "Risk Factors" to better understand the risks and uncertainties that are inherent in our business and in owning our securities.

Any forward-looking statements which we make in this report or in any of the documents that are incorporated by reference herein speak only as of the date of such statement, and we undertake no ongoing obligation to update such statements. Comparisons of results between current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

## PART I

### Item 1. Business

#### General

Symmetry Medical Inc. (which we sometimes refer to, together with our consolidated subsidiaries, as the "Corporation," "we," "our" or "Symmetry") is a leading independent provider of implants and related instruments and cases to global orthopedic device manufacturers. We design, develop and produce these products for companies in other segments of the medical device market, including the arthroscopy, dental, laparoscopy, osteobiologic and endoscopy segments, and we also provide limited specialized products to non-healthcare markets, such as the aerospace market. Our Total Solutions® concept provides our customers with a collaborative process for developing complete implant systems, including the implant, the surgical instruments, and the related case. This approach presents our customers with a broad range of products, as well as comprehensive design, engineering and project management services and state of the art production capabilities to help them bring their systems to market quickly and efficiently. We believe that our close customer relationships, broad product offering and leading quality and regulatory performance give us a competitive advantage.

During fiscal year 2010, we generated revenue of \$360.8 million, derived primarily from the sale of products to the orthopedic device market and other medical markets. Our Total Solutions® approach is supported by an experienced team of designers, development engineers, logistics specialists and by our global sales force that works with our customers to coordinate all of our products.

Our primary products include:

- implants, including forged, cast and machined products for the global orthopedic device market;
- instruments used in the placement and removal of orthopedic implants and in other surgical procedures;
- cases, including plastic, metal and hybrid cases used to organize, secure and transport medical devices for orthopedic, endoscopy, dental and other surgical procedures; and
  - other specialized products for the aerospace market.

#### History

Our business was established in 1976 as a supplier of instruments to orthopedic device manufacturers. Symmetry Medical Inc. was incorporated in Delaware on July 25, 1996. Over the past five years, we have made several acquisitions which expanded our customer base, enhanced our product offerings and extended our product lines.

In 2006, we acquired Riley Medical and Everest Metal. Riley Medical specializes in cases and trays for the orthopedic industry and the acquisition of Riley Medical included many patented products and expanded our product offering of medical cases and trays to the medical markets. Everest Metal specializes in finishing implants for the orthopedic industry.

During 2007, we acquired Clamonta Ltd., TNCO, Inc., Specialty Surgical Instrumentation, Inc. and UCA, LLC. Clamonta Ltd. machines products for the global aerospace industry. TNCO was a privately owned company with a 40-year history of designing and supplying instruments for arthroscopic, laparoscopic, sinus and other minimally invasive procedures. TNCO allows us to leverage our instrument manufacturing while also leveraging their customer base in non-orthopedic segments of the healthcare market. Specialty Surgical Instrumentation, Inc. and UCA, LLC (collectively "SSI") located in Nashville, Tennessee distributes surgical instruments and sterilization containers directly to hospitals. The addition of SSI allows us to offer a broad array of medical instruments and related products to our customer base. This includes over 13,000 individual items, many of which are held in inventory for quick delivery. For Symmetry, this was our first entry into the medical product distribution industry, which provides us direct access to hospitals.

In January of 2008, we acquired DePuy Orthopaedics, Inc.'s New Bedford, Massachusetts instrument manufacturing facility ("New Bedford") for approximately \$45.2 million. This facility manufactures orthopedic instruments as well as general surgical instruments and small implants. In connection with the acquisition, we entered into a supply agreement which, starting January 25, 2008, requires DePuy to make minimum purchases totaling \$106 million from New Bedford for a four year period, with specific amounts in each year. The agreement stipulates that these purchases are incremental to other products we previously produced on DePuy's behalf. These minimum purchases have been met each year since acquisition.

#### Our Total Solutions® Approach

We believe that we have created a distinct competitive position in the orthopedic device market based upon our Total Solutions® approach. Our Total Solutions® approach presents our customers with a broad range of products, as well as comprehensive design, engineering and project management services and state of the art production capabilities to help bring their implant systems to market quickly and efficiently.

Our Total Solutions® offering is based on:

- **Comprehensive Offerings.** We can support our customers' new product offerings from product concept through market introduction and thereafter, by providing seamless design, engineering, prototyping and manufacturing offerings.
- **Single Source for Complete Systems.** We assist our customers in developing new implants, and we design and produce instruments for implant-specific surgical procedures. We also provide customized cases that provide a secure, clearly labeled and well organized arrangement of instruments and devices.
- **Proprietary Symmetry Instruments and Cases.** Our established lines of proprietary products allow our customers to complete their proprietary implant systems and bring them to market sooner.
- **Precision Manufacturing Expertise.** Our extensive expertise and know-how enable us to produce large volumes of specialized products to our customers' precise standards, which we believe makes us a supplier of choice to the largest orthopedic companies. Our core production competencies include net shaped forging, precision casting, thermo forming, precision sheet metal working and machining/finishing. Over the past several years, we developed high precision machining capabilities to better serve the spine implant market.
- **Quality and Regulatory Compliance.** Our quality systems are based upon and in compliance with International Organization for Standardization ("ISO") requirements and, where applicable, United States Food and Drug Administration ("FDA") regulations. We believe our level of quality and regulatory compliance systems meet or exceed our customers' expectations. We continue investing in this area to strengthen our leadership position.
- **Global Reach.** Our manufacturing capabilities in the United States, United Kingdom, France, Ireland and Malaysia allow us to offer single-source products to our multinational customers, and the geographic breadth of our experienced sales force effectively brings our Total Solutions® approach to customers around the globe.

We believe that our Total Solutions® approach offers a number of benefits to our customers, including:

- **Shorter Time to Market.** Our design, engineering and prototyping skills, as well as our ability to transition seamlessly from product development to production of implants, instruments and cases, enable our customers to reduce time to market for their new products.
- **Reduced Total Product Acquisition Costs.** Our comprehensive offerings, including design, engineering, prototyping, project management, production and inventory control, allow our customers to reduce their procurement costs and inventory levels, resulting in lower product acquisition costs.
- **Increased Focus on Marketing and Research and Development Efforts.** Our extensive production capabilities and comprehensive offerings provide a one-stop outsourcing solution and allow our customers to focus their resources on their design, development and marketing efforts.
- **Rationalized and Reliable Supply Chain.** Our scale, scope of products and Total Solutions® approach allow large orthopedic companies to reduce their number of independent suppliers and streamline their operations.
- **Enhanced Product Consistency on a Global Basis.** Our extensive production platform, Total Solutions® approach and international presence allow us to meet global demand for orthopedic devices, which is expected to continue to increase.



Over the past several years, we have further developed our Total Solutions® offering through strategic acquisitions which expanded our product offerings to include medical cases and trays to non-orthopedic medical markets, additional patented products, enhanced implant finishing capabilities and minimally invasive instrumentation.

#### Business Strategy

Our goal is to increase our share of the orthopedic device market and to leverage our strengths to expand in other medical device market segments. The key elements of our business strategy are to:

- **Develop Strategic Relationships With Our Customers Through Access to Key Decision Makers.** Our scale, scope of products and Total Solutions® approach positions us as an important partner to our customers. This position gives us access to key decision makers with whom we intend to continue to build strategic relationships.

- **Capitalize on Our Total Solutions® Approach.** We believe that our Total Solutions® approach shortens product development cycles, reduces design and manufacturing costs, and simplifies purchasing and logistics, and we intend to aggressively market these benefits to our customers.
- **Increase Sales to Existing Customers by Cross Selling Products and Offerings.** Our cases are currently sold in nearly every segment of the medical device market. We believe that our diverse customer base offers us a natural entry point to new orthopedic and non-orthopedic customers for our implants and instruments.
- **Leverage Manufacturing Skills.** During recent years, we have continued to expand our manufacturing capacity and design resources, and updated much of our manufacturing and development equipment. We intend to continue to leverage our investments in sophisticated equipment and manufacturing know-how to expand our existing customer relationships and to obtain new customers. During the past several years, we developed high precision machining capabilities to better serve the spine implant market.
- **Increase New Product Offerings.** Our Design and Development Centers provide expertise and coordination for our design, engineering and prototyping offerings. We intend to use the dedicated expertise of our Design and Development Centers to generate additional development projects with our customers and to expand our line of innovative and independently developed instruments and cases.
- **Collaborate With Emerging Companies.** We believe that new and innovative medical device companies are creating a meaningful market presence and that our Total Solutions® approach positions us to help these companies, many of which may have limited resources, manage their product manufacturing and logistic services.
- **Continued Global Expansion.** Our global facilities allow us to serve the global medical marketplace. We believe that having local facilities near our global customers and closer to the end consumer allows us to better serve their needs. In December 2006, we opened a facility in Malaysia to better serve our customers in Asia. We are continuing to expand our Malaysian operations and increase its product offerings.
- **Leverage Technology.** Our expertise in metal processing and in particular high integrity net shape forging enables us to develop a role as a niche supplier in certain other markets, most notably the aerospace sector, where we supply engine aerofoil blades and other similar parts.
- **Expand Our Sales Channels to Market.** Our 2007 acquisition of SSI in Nashville, Tennessee has created an opportunity to sell a range of products that we procure and manufacture directly to hospitals.

## Products

We design, develop and manufacture implants and related surgical instruments and cases for orthopedic device companies. We also design, develop and manufacture products for companies in other medical device markets, such as dental, osteobiologic and endoscopy, and we provide specialized products used in the aerospace market. We also market and sell highly specialized operating room products, such as instrumentation, fiber optic light sources and non-toxic enzymatic detergent, targeted directly to surgeons. Our revenue from the sale of instruments, implants, cases and other products represented 40.3%, 30.8%, 22.7% and 6.2%, respectively, of our revenue in fiscal 2010, compared with 45.6%, 29.5%, 18.7% and 6.2%, respectively, of our revenue in fiscal 2009.

## Implants

We design, develop and manufacture implants for use in specific implant systems developed by our customers. We make orthopedic implants used primarily in knee and hip implant systems. Our orthopedic implants are used in

reconstructive surgeries to replace or repair hips, knees and other joints, such as shoulders, ankles and elbows (sometimes referred to as extremities), that have deteriorated as a result of disease or injury. An orthopedic implant system is generally comprised of several implants designed to work in concert to replicate the structure and function of a healthy joint.

We also manufacture implant products for trauma, spine and other implant systems. Trauma implant systems are used primarily to reattach or stabilize damaged bone or tissue while the body heals. Spinal implant systems are used by orthopedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities and injuries in various regions of the spine.

Our design, engineering and prototyping expertise is an integral part of our implant offering. Medical device companies, which typically focus their resources on developing new implant systems as well as sales and marketing, may rely on us and companies like us to design, develop and manufacture the implants that comprise their implant systems. Our manufacturing capabilities, including our net shaped forging capabilities, technologically advanced casting facility and machining expertise, allow us to produce consistent, tight tolerance implants in large volumes for our customers.

We produce gross shaped, near-net shaped and net shaped implants for medical device manufacturers. Gross shaped implants require a significant amount of machining and hand processing post-forging. Near-net shaped implants are distinguished by geometric features that are thinner, more detailed and have tighter tolerances. Net shaped and near-net shaped implants require far fewer machine and hand operations post-forging. Net shaped implants typically require machining only on vital areas, such as the taper segment of a hip where it is joined to the femoral head.

We have the machining expertise needed to provide finished implants to our customers. Some customers purchase finished implants from us while others purchase unfinished implants and machine them to final specifications.

Our primary implant products and their applications are:

- **Knees.** The knee joint includes the surfaces of three distinct bones: the lower end of the femur, the upper end of the tibia or shin bone, and the patella (knee cap). Cartilage on any of these surfaces can be compromised by disease or injury, leading to pain and inflammation that may require knee reconstruction. Our knee implants include a femoral component, a patella, a tibial tray and an articulating surface (placed on the tibial tray) and are used in total knee reconstruction, partial knee reconstruction and revision procedures. We provide one or more, and in some cases, all of these implants for our customers' knee implant systems. We use proprietary manufacturing know-how and advanced computer aided simulation techniques to produce tight tolerance near-net shaped to net shaped tibial implants that require minimal if any machining.
- **Hips.** The hip joint consists of a ball-and-socket joint that enables a wide range of motion. The hip joint is often replaced due to degeneration of the cartilage between the head of the femur (the ball) and the acetabulum or hollow portion of the pelvis (the socket). This loss of cartilage causes pain, stiffness and a reduction in hip mobility. We produce tight tolerance femoral heads, hip stems, acetabular cups and spiked acetabular cups used in bone conservation, total-hip reconstruction and revision replacement procedures. Our hip stems are forged with tight tolerance details.
- **Extremities, Trauma and Spine.** Extremity reconstruction involves the use of an implant system to replace or reconstruct injured or diseased joints, such as the finger, toe, wrist, elbow, foot, ankle and shoulder. Our forging capabilities allow us to produce thin cross sections of material to very tight tolerances for these smaller joint procedures. Trauma implant procedures commonly involve the internal fixation of bone fragments using an assortment of plates, screws, rods, wires and pins. Our spinal implant products consist primarily of plates and screws. We manufacture trauma and spinal plate implants to exact details to fit bone contours. We have in place a high precision machining cell to serve the spine market.

## Instruments

We make high-precision surgical instruments used in hip, knee and shoulder reconstruction procedures, as well as in spinal, trauma and other implant procedures. We design, develop and manufacture implant-specific and procedure-specific instruments. In addition, we have several orthopedic reamer systems used by many of our large customers. We typically do not manufacture general surgical instruments, but will procure them as an offering to our customers in order to provide our customers with complete instrument sets. We also market and sell highly specialized

operating room instrumentation targeted directly to specialty surgeons. We currently have over 1,500 Symmetry standard products in our catalog plus over 13,000 individual items sold directly to hospitals.

We produce a wide variety of products, primarily knee cutting blocks (instruments that guide blades that cut bone), osteotome revision systems (instruments used to cut through bone), reamers (instruments used for shaping bone sockets or cavities) and retractors (instruments used to pull back tissue for clear sight during surgery). Some of our instrument handles are made with our patented plastic insertion machine, which is designed to withstand the intense heat produced during frequent sterilizations and is attached to the instrument. Our instruments are made to tight tolerances to ensure precise alignment and fitting of implants.

Each implant system typically has an associated instrument set that is used in the surgical procedure to insert that specific implant system. Instruments included in a set vary by implant system. For example, hip and knee implant procedure instrument sets often contain in excess of 100 instruments, whereas revision procedure sets may contain approximately 50 instruments. Usually, instrument sets are sterilized after each use and then reused.

The instruments we produce are typically used in either open, minimally invasive, or revision implant procedures and can generally be categorized as:

- Implant-specific instruments, which are used solely for a specific brand of implant, such as high-precision knee cutting blocks, certain reamers and broaches; and
- Procedure-specific instruments, which are designed for a particular type of procedure, such as a minimally invasive hip implant procedure, but can be used with the implant systems of multiple companies.

**Implant-Specific Instruments.** The size, shape and other features of each implant system are unique. Consequently, unique instruments must be used to ensure precise alignment and fitting during the surgical procedure to insert an implant system. Accordingly, when a medical device company develops a new implant system, it typically also develops instruments specifically designed to insert the implant system. Medical device companies typically provide complete, customized implant-specific instrument sets to end users (hospitals, outpatient centers and physicians) in order to facilitate use of the implant.

We seek to collaborate with our customers early in the development process to facilitate the concurrent design of the implant system and the instruments that will accompany the system. Our implant-specific instruments generally include customized reamers, cutting blocks, broaches, rasps, guides and other instruments designed to accommodate the unique size, shape and other features of our customers' implant systems. These instruments are used by the surgeon to cut and shape bone and cavities during the surgical procedure and to align and fit the implant system. We are recognized in the orthopedic community for constructing these instruments to extremely tight tolerances.

**Procedure-Specific Instruments.** We also manufacture independently developed instruments referred to as our Symmetry products. We have developed these products through our years of experience serving the orthopedic market and our investments in research and development. Complete implant procedure instrument sets typically include certain instruments that are designed for a particular type of procedure but can be used with the implant systems of multiple companies. By purchasing our proven Symmetry products, customers can leverage our extensive experience and expertise to complete their instrument sets more quickly and efficiently.

Our Symmetry products include successful hip and knee revision systems. Instruments that make up revision systems, which are used to remove orthopedic implants, are typically designed for a specific type of procedure but can be used to remove various brands of implants. These self-contained systems include an assortment of osteotome blades that assist the surgeon in separating an implant from cement or bone in-growth where access is limited, while minimizing damage to the bone. Our established revision systems can also be readily modified for a customer by adding additional instruments. In recent years we have seen our Symmetry product sets grow in demand as our large OEM customers distribute the products and we maintain the device files.

**Specialty Surgical Instrumentation.** We distribute a wide array of instruments and related products directly to hospitals. These instruments comprise cutting, dissecting, grasping, cauterizing, ligating, coagulating, hot blade cutting, bi-polar and mono-polar instruments as well as reusable and disposable instruments. Most of these instruments are sold into operating room settings, including neurology, ophthalmology, rhinoplasty, reconstructive, cardiovascular, thoracic, vascular, laparoscopic, and gynecology.

#### Cases

We produce a wide range of plastic, metal and hybrid cases used in over 25 medical device markets, including orthopedic, spinal, arthroscopy, osteobiologic, endoscopy, cardiovascular, dental, ophthalmology, diagnostic imaging and ear, nose and throat surgical procedures. Cases are used to store, transport and arrange implant systems and other medical devices and related surgical instruments. Our cases are generally designed to allow for sterilization and re-use after an implant or other surgical procedure is performed. Our plastic cases are designed to withstand the intense heat

produced during the sterilization process.

Many of the cases we make are tailored for specific implant procedures so that the instruments, implants and other devices are arranged within the case to match the order of use in the procedure and are securely held in clearly labeled, custom-formed pockets. We seek to collaborate with our customers early in the development processes to facilitate the concurrent design of the case and related instruments.

We also produce standard cases which are primarily used in the non-orthopedic market segments where the security or presentation of the instruments and devices is not customized for a specific surgery. Over the past several years, we have made a significant investment to obtain 510(k) clearance for our line of standard cases through the FDA pre-market notification process. We believe this allows our customers to reduce time to market and to reallocate financial and human resources that would otherwise be spent on compliance efforts, which provides us with a significant competitive advantage in selling our standard cases.

We have 40 patents related to our case designs and manufacturing processes. We believe that our complete line of plastic, metal and hybrid product offerings strategically positions us in the case market. We also offer medical containers which are used by hospitals to hold instruments when they are sterilized.

Highlights of our case product offerings include:

- **Orthopedic Cases.** We produce custom metal, plastic and hybrid cases designed to store, transport and arrange surgical instruments and related implant systems for orthopedic device manufacturers. Proper identification of instruments, such as reamers which are generally included in a range of sizes in one to two millimeter increments, is critical in orthopedic implant procedures. Our graphics and thermo formed tray pockets provide a secure and organized arrangement to assist surgeons during procedures.
  - **Endoscopy Cases.** We produce cases for endoscope sterilization for many types of sterilization methods.
- **Dental Cases.** We produce cases used in dental implant and general dental procedures. Dental implant cases are typically complex and include many levels of trays, while cases used in general dental procedures tend to be smaller and less complex.
- **Sterilization Containers.** We produce lightweight and durable Ultra Container System which is designed for the sterilization of all surgical instruments. This product is primarily sold directly to hospitals.
- **Other Cases.** We also manufacture and sell cases for arthroscopy, osteobiologic, cardiovascular, ophthalmology, diagnostic imaging and ear, nose and throat procedures.

#### Specialized Non-Healthcare Products

We offer specialized non-healthcare products on a limited basis. Our core design, engineering and manufacturing competencies give us the expertise to offer aerospace products. Our aerospace products primarily are net shaped aerofoils and non-rotating aircraft engine forgings produced for our aerospace customers. Additionally, our offering in the aerospace industry includes aerospace machining capabilities.

#### Product Development

Our Design and Development Centers provide dedicated expertise and greater coordination for our design, engineering and prototyping offerings. Our main Design and Development Center is located in Warsaw, Indiana, and brings together talented engineering and design personnel and provides them with state-of-the-art design software and prototyping equipment. Our Design and Development Centers serve to centralize and better institutionalize our design and engineering knowledge and create a fertile environment for new product development. We can coordinate the product development projects for our customers as well as the efforts of our engineers and designers in order to ensure that we have the appropriate people and technology focused on particular product development initiatives. We seek to collaborate with our customers' product development teams and to assist in the design, engineering and prototyping of new medical device systems from the beginning of the development process. Our sales staff is technically trained and works closely with our customers' staff. As new product concepts are formulated, our sales people bring in our design and engineering personnel and utilize the resources of our Design and Development Centers to provide dedicated design teams with exceptional knowledge and experience. As a project evolves, we can rapidly create prototypes of the proposed product, instrument, case or implant. Working closely with our customers through the conceptual, planning and prototyping stages allows us to quickly scale up for manufacturing of the product.

In addition to supporting our customers' product development efforts, our Design and Development Centers are continuously developing our own product lines, which we refer to as Symmetry products. We develop products by utilizing years of experience and knowledge, investing in research and development and continually seeking to expand our knowledge of the marketplace by consulting surgeons and other end users of our products. We currently offer over 1,500 Symmetry products, including instruments for minimally invasive surgical implant procedures and hip and knee



revision systems.

#### Environmental Issues

Our discussion of environmental issues is presented under the caption "Environmental" in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations in this Form 10-K.

#### Capital Investment

Information concerning our capital expenditures is presented under the caption "Capital Expenditures" in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations in this Form 10-K.

#### Customers

We supply our products primarily to manufacturers in the medical device market. Our customers include large orthopedic device manufacturers, including Biomet Inc., DePuy Orthopaedics, Inc., a subsidiary of Johnson & Johnson, ("DePuy"), Medtronic Inc., Smith & Nephew Plc, Stryker Corp. and Zimmer Holdings, Inc. ("Zimmer"). We also have established relationships, primarily through our case product offerings, with leading medical device manufacturers and distributors in numerous other medical device market segments, including Cardinal Health, Inc., Karl Storz, Edward Lifesciences and St. Jude Medical Inc. With the addition of SSI in August 2007, we serve over 1,000 additional customers, some of which own multiple hospitals.

We sold to approximately 1,850 customers in fiscal 2010. Sales to our ten largest customers represented 71.3% and 73.1% of our revenue in fiscal 2010 and 2009, respectively. Our three largest customers accounted for 31.7%, 10.5% and 10.0% of our revenue in fiscal 2010 and were, in alphabetical order, DePuy, Stryker Corp and Zimmer. In 2009, our largest customer, DePuy, accounted for 39.1% of our revenue. No other customer, other than those stated above, accounted for more than 10% of our revenue in fiscal 2010 or fiscal 2009. We typically serve several product teams and facilities within each of our largest customers, which mitigates our reliance on any particular customer. Over the past five years, we have reduced our concentration in the orthopedic industry through various acquisitions, which increased our presence in non-orthopedic markets.

We sell our products to customers domestically and in a number of regions outside the United States. In addition, our customers often distribute globally products purchased from us in the United States. Set forth below is a summary of percent of revenue by selected geographic locations in our last three fiscal years, based on the location to which we shipped our products:

	Fiscal Year Ended		
	2010	2009	2008
United States			

(2) Reflects payment for lodging and meals for attending a director education session.

- (3) Mr. Floyd retired from the Board effective May 19, 2009.
- (4) Mr. Kirbo resigned from the Board effective November 16, 2009.
- (5) Mr. Williford was appointed to the Board effective December 15, 2009.

**Table of Contents****EXECUTIVE OFFICERS**

The following table sets forth certain information regarding each executive officer of the Company.

<b><u>Name, Age and Term as Officer</u></b>	<b><u>Position</u></b>	<b><u>Principal Occupation for the Last Five Years and Other Directorships</u></b>
Edwin W. Hortman, Jr., 56 Officer since 2002	President and Chief Executive Officer	President and Chief Executive Officer since January 1, 2005. Director since November 2003. President and Chief Operating Officer from November 2003 through December 2004. Executive Vice President and Regional Bank Executive for Northern Division from August 2002 through November 2003. President, Chief Executive Officer and Director of Citizens Security Bank from April 1998 to November 2003. Director of each subsidiary bank in the Northern Division from September 2002 through March 2004.
Dennis J. Zember Jr., 40 Officer since 2005	Executive Vice President and Chief Financial Officer	Executive Vice President and Chief Financial Officer since February 14, 2005. Senior Vice President and Treasurer of Flag Financial Corporation and Senior Vice President and Chief Financial Officer of Flag Bank from January 2002 to February 2005. Vice President and Treasurer of Century South Banks, Inc. from August 1997 to May 2001.
Andrew B. Cheney, 60 Officer since 2009	Executive Vice President and Banking Group President	Executive Vice President and Interim Banking Group President since May 2009. Regional Executive for Florida and Coastal Georgia from February 2009 to May 2009. Florida Chairman from January 2008 to January 2009 and President from January 2000 to December 2007 with Mercantile Bank.
Marc J. Bogan, 43 Officer since 2006	Executive Vice President and Chief Operating Officer	Executive Vice President and Chief Operating Officer since June 2008. Coastal Region Executive from September 2006 to June 2008. Sales Executive with South Carolina Bank and Trust from April 2004 to September 2006. Regional President for South Carolina Bank and Trust from June 2001 to April 2004.

**Table of Contents**

<b>Name, Age and Term as Officer</b>	<b>Position</b>	<b>Principal Occupation for the Last Five Years and Other Directorships</b>
Jon S. Edwards, 48  Officer since 1999	Executive Vice President and Director of Credit Administration	Executive Vice President and Director of Credit Administration since May 2005. Executive Vice President and Regional Bank Executive for Southern Division from August 2002 through April 2005. Director of Credit Administration from March 1999 to July 2003. Senior Vice President from March 1999 to August 2002. Director of each subsidiary bank in the Southern Division from September 2002 through April 2005.
Cindi H. Lewis, 56  Officer since 1987	Executive Vice President, Chief Administrative Officer and Corporate Secretary	Chief Administrative Officer since May 2006, Executive Vice President since May 2002 and Corporate Secretary since May 2000. Director of Human Resources from May 2000 to May 2006 and Senior Vice President from May 2000 to May 2002.

**EXECUTIVE COMPENSATION**

**COMPENSATION DISCUSSION AND ANALYSIS**

*The following Compensation Discussion and Analysis may contain statements regarding future individual and Company performance targets or goals. We have disclosed these targets or goals in the limited context of the Company's compensation programs; therefore, you should not take these statements to be statements of management's expectations or estimates of results or other guidance. We specifically caution investors not to apply such statements in other contexts.*

This Compensation Discussion and Analysis is intended to assist our shareholders in understanding the Company's compensation programs. It presents and explains the philosophy underlying our compensation strategy and the fundamental elements of compensation paid to our Chief Executive Officer, Chief Financial Officer and other individuals included in the Summary Compensation Table (collectively, named executive officers) for 2009. Specifically, this Compensation Discussion and Analysis addresses the following:

our compensation philosophy and the objectives of our compensation programs;

what our compensation programs are designed to reward;

our process for determining executive officer compensation, including:

the role and responsibility of the Compensation Committee;

the role of the Chief Executive Officer and other named executive officers;

the role of compensation consultants; and

benchmarking and other market analyses;

elements of compensation provided to our executive officers, including:

the purpose of each element of compensation;

why we elect to pay each element of compensation;

**Table of Contents**

how we determine the levels or payout opportunities for each element; and

decisions on final payments for each element and how these align with performance; and

other compensation and benefit policies affecting our executive officers.

**Compensation Philosophy and the Objectives of Our Compensation Programs**

The Compensation Committee believes that the most effective compensation programs strive to accomplish the following objectives:

aligning the interests of the employee with those of the Company's shareholders;

attracting and retaining talented individuals and top performers; and

motivating performance toward the achievement of short-term and long-term goals.

To meet these objectives, the Compensation Committee has carefully structured the programs in the following manner:

base compensation levels comparable and competitive to the 50<sup>th</sup> percentile of market, defined both in terms of geography, company type and company size;

annual incentive compensation that varies in a consistent manner with the achievement of both individual performance objectives and the financial results of the Company;

long-term incentive compensation (equity) based on the achievement of longer-term (minimum three-year) financial and strategic goals;

executive benefits that are meaningful, competitive and comparable to those offered by similar organizations; and

an appropriate balance between base pay, short-term incentives, long-term incentives and benefits that provides total compensation at a percentile of market compensation levels that approximates the Company's performance relative to its regional peers.

In designing and administering the Company's executive compensation programs, the Compensation Committee strives to maintain an appropriate balance across all of the various compensation elements, realizing that at times some objectives may be in conflict with others. In addition, external factors, such as the unanticipated downturn in the economy continuing through 2009 or legislative changes impacting executive compensation programs, may impact the effectiveness of existing approaches to executive compensation. Such events require a careful reconsideration of existing approaches, and on an annual basis the Compensation Committee may make decisions and adjustments to future compensation programs to maintain the strategic objectives of executive compensation.

**What Our Executive Compensation Program is Designed to Reward**

Our executive officers' compensation program uses different components to reward different performance considerations. Base salary is provided to reward the executives for daily contributions and the application of their knowledge, experience and talent to the success of the Company. Base salary is also a reflection of the executives' external value in the job market and the internal value of their assigned roles and responsibilities to the success and ongoing viability of the Company.

Annual incentives are provided to focus performance on the key strategic short-term objectives defined and established on an annual basis. These incentives are strongly linked to the success of achieving annual goals and provide the executive with cash rewards commensurate with the Company's annual performance and the Board's assessment of the executive's personal performance. As a result of compensation limitations applicable to the

---

**Table of Contents**

Company because of its participation in the Troubled Asset Relief Program ( TARP ), we were unable to incorporate annual cash-based incentive pay into our compensation program for named executive officers in 2009.

Long-term incentives reward executives for the longer-term success of the Company. During the past three years, long-term incentives have been provided in the form of stock options and restricted stock with both time-based and performance-based vesting provisions. This equity-based compensation rewards executives for the long-term performance of the Company and maintains the alignment between executive compensation levels and shareholder value. As the value of the stock held by shareholders increases, the value of the equity-based long-term incentives provided to each executive increases. Conversely, as shareholder value declines, the value of the equity awards vesting for each executive declines. As a result of TARP limitations, however, the Company is prohibited from using stock options as incentive compensation and is limited in its ability to use restricted stock, which may not exceed one-third of total compensation for a named executive officer.

Benefits provided to each executive officer are in line with our broad-based employee benefits which meet basic health and welfare needs. Perquisites for our executives remain conservative and primarily serve to enhance our executives' business development activities.

**TARP Compensation Requirements**

On June 10, 2009, the United States Department of the Treasury (the Treasury ) published an interim final rule, which became effective June 15, 2009, applicable to the Company and other financial institutions participating in the Capital Purchase Program under TARP with respect to executive compensation and corporate governance standards imposed by the Emergency Economic Stabilization Act of 2008 ( EESA ), as amended by the American Recovery and Reinvestment Act of 2009 ( ARRA ). On November 21, 2008, the Company received \$52 million in TARP funds by issuing to the Treasury preferred stock and a warrant exercisable for shares of Common Stock. The following summary addresses certain requirements that are applicable to the Company under EESA as a TARP recipient for so long as any obligation arising from funds provided to the Company remains outstanding under TARP (the TARP period ).

For purposes of EESA, Senior Executive Officers ( SEOs ) are the top five most highly compensated executives of a public company whose compensation is required to be disclosed pursuant to SEC regulations, which for the Company will generally be the same individuals as those comprising the named executive officers presented in this Proxy Statement or future proxy statements. The requirements related to executive compensation are as follows:

*Limits on Incentive Compensation* The scope of limits on incentive compensation vary based upon the amount of funds received under TARP. In our case, we are prohibited from paying or accruing any bonus, retention award or incentive compensation for any of our five most highly compensated employees (the SEOs). This prohibition does not apply (i) to any bonus payments required to be paid pursuant to a written employment agreement executed on or before February 11, 2009; or (ii) to the granting of long-term restricted stock, provided that such restricted stock does not fully vest during the TARP period and is not awarded on an annual basis at a value exceeding one-third of the covered employee's total annual compensation.

*Prohibition on Compensation that Provides an Incentive to Take Unnecessary and Excessive Risks* This restriction prohibits the participating financial institution from providing incentive compensation arrangements that encourage SEOs to take unnecessary and excessive risks that threaten the value of the financial institution. Treasury regulations also require the institution's compensation committee to review SEO incentive compensation arrangements with its senior risk officers to ensure that the SEOs are not encouraged to take such risks. The regulations require the institution's compensation committee to meet at least semi-annually with its senior risk officers to discuss and review the relationship between its risk management policies and practices and the SEO incentive compensation arrangements. The





---

**Table of Contents**

Compensation Committee has performed this review, and its conclusions are included in its report in this Proxy Statement.

*Clawback on Incentive Compensation* Compensation plans must provide for the recovery of any bonus, retention award or incentive compensation paid to CEOs and the next 20 most highly compensated employees (up to a total of 25 employees) that were based upon financial statements or other criteria that are later to be found to be materially inaccurate. In addition, compensation plans that would encourage manipulation of reported earnings to enhance the compensation of any employee are prohibited.

*Limit on Tax Deduction* This provision of EESA limits the tax deduction for compensation paid to any CEO to \$500,000 annually. This provision of EESA amended Section 162(m) of the Internal Revenue Code by adding Section 162(m)(5), which sets forth the \$500,000 deduction limit. In addition, prior to the amendment, certain performance-based compensation paid under shareholder-approved plans did not count toward such deduction limit. EESA and Section 162(m)(5) eliminate that exclusion for the Company.

*Prohibitions on Golden Parachutes* TARP recipients are prohibited from making any golden parachute payments to CEOs and the next five most highly compensated employees (up to a total of ten employees). Golden parachute payments are defined as any payment for departure from a company for any reason, except for payments for services performed or benefits accrued. In addition, any amount due upon a change in control event of a TARP recipient, as well as the acceleration of vesting due to a departure or a change in control event, is treated as a golden parachute payment. The estimated impact of this prohibition on the named executive officers is set forth in the portion of this Proxy Statement titled "Potential Payments Upon Termination or Change in Control".

*Limitations on Luxury Expenditures* A TARP recipient must have a policy regarding excessive or luxury expenditures, including entertainment or events, office and facility renovations, aviation or other transportation services, and other activities or events that are not reasonable expenditures for staff development or reasonable performance incentives. The Company has adopted a policy on excessive or luxury expenditures, which is available on its website at [www.amerisbank.com](http://www.amerisbank.com). For more details on the extent of perquisites and other expenditures provided to our CEOs, see the supplementary table on perquisites which follows the Summary Compensation Table below.

*Prohibition of Tax Gross-Ups* TARP recipients are prohibited by the from providing gross ups to any CEO and the next 20 most highly compensated employees. This requirement prohibits the reimbursement of taxes owed on any compensation, such as golden parachutes and perquisites.

*Non-Binding Advisory Proposal on Executive Compensation* As required by ARRA, the Board authorized a non-binding advisory shareholder vote on the Company's executive compensation plans, programs and arrangements. This proposal is included in this Proxy Statement.

Each of our CEOs and other affected employees has executed an agreement that reduces his compensation and other benefits, and includes appropriate clawback provisions, to the extent necessary to comply with EESA and ARRA requirements. These agreements will remain in effect throughout the TARP period.

**Compensation Program Risk**

The Company also reviews its compensation policies and practices in accordance with SEC guidance to identify instances in which its compensation plans may encourage participants to take risks that are reasonably likely to have a material adverse effect on the Company. This review extends to not only our senior executive officers but also all other employees. With the assistance of the Company's Senior Risk Officer and compensation consultants engaged by the Compensation Committee, we reviewed the purpose of each short-term and long-term compensation plan, eligible participants in each plan, how we assigned administrative authority for each plan, categories of performance

measures in each plan and incentive award opportunity levels. In addition,

## **Table of Contents**

our compensation consultant, Matthews, Young & Associates, Inc. ( Matthews Young ), reviewed the competitiveness and mix of compensation elements in our overall executive compensation program and reported to the Compensation Committee during the fourth quarter of 2009. As a result of our review, we determined that (i) there is balance in our overall compensation mix; (ii) executive officer base salaries are appropriately competitive without need to earn a high level of bonus or incentive in order to earn adequate cash compensation; (iii) our use of equity grants as long-term incentives provides an effective and balanced focus between short- and long-term objectives; and (iv) the Company's compensation policies, plans and practices do not encourage unnecessary or unreasonable risk-taking and do not encourage executives or employees to take risks that are reasonably likely to have an adverse effect on the Company.

### **Process for Determining Executive Officer Compensation**

#### **Role of the Compensation Committee**

The Compensation Committee administers the Company's executive compensation programs. During 2009, the Compensation Committee consisted of J. Raymond Fulp (Chairman), Daniel B. Jeter and Glenn A. Kirbo. In November of 2009, Mr. Kirbo resigned from the Board of Directors, and Mr. Veal has assumed Compensation Committee responsibilities for 2010. The members of the Compensation Committee all qualify as independent, outside members of the Board in accordance with the requirements of Nasdaq, current SEC regulations and Section 162(m) of the Internal Revenue Code.

The Compensation Committee is responsible for all compensation decisions for the Chief Executive Officer and the other named executive officers. The Compensation Committee annually reviews the levels of compensation along with the performance results on goals and objectives relating to compensation for the named executive officers. Based on this evaluation, the Compensation Committee makes decisions related to executive compensation programs with final approval by the Board.

Additionally, the Compensation Committee periodically reviews our incentive plans and other equity-based plans. The Compensation Committee reviews, adopts and submits to the Board any proposed arrangement or plan and any amendment to an existing arrangement or plan that provides or will provide benefits to the executive officers collectively or to an individual executive officer. The Compensation Committee has sole authority to retain and terminate compensation consultants and other advisors as it deems appropriate.

#### **Role of the Executive Officers**

The Chief Executive Officer, with the assistance of the Company's Chief Administrative Officer, annually reviews the performance of the other named executive officers, after which the Chief Executive Officer presents his conclusions and recommendations to the Compensation Committee for approval. The Compensation Committee has absolute discretion as to whether it approves the recommendations of the Chief Executive Officer or makes adjustments, as it deems appropriate. The Chief Executive Officer, Chief Financial Officer and Chief Administrative Officer may also work with the Compensation Committee to gather and compile data needed for benchmarking purposes or for other analysis conducted by the Compensation Committee's independent consultants and advisors.

#### **Role of Compensation Consultants**

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

In making compensation decisions for 2009, the Compensation Committee engaged Matthews Young to conduct an overall compensation review for the Company's top executive employees, including the named executive officers. In addition to the Matthews Young detailed review of executive compensation, Blanchard Chase & Associates, LLC (Blanchard Chase) provided a supplementary independent analysis of executive compensation levels.

**Table of Contents**

The Compensation Committee also worked with Matthews Young in the review and analysis of risk in the Company's compensation programs. Matthews Young, working in coordination with our Senior Risk Officer, provided a comprehensive risk assessment of compensation programs throughout the Company. Matthews Young reported directly to the Compensation Committee on all work conducted and performed no other services for the Company in 2009.

Both the Board and the Compensation Committee received assistance with the proxy disclosure process from CompWiser Consulting, LLC (CompWiser). CompWiser was chosen and retained by the Board and reported directly to the Board. Throughout the disclosure process, CompWiser coordinated the collection of compensation data, policies and plans with the Board and senior management of the Company.

The three compensation consulting firms retained by the Board and the Compensation Committee are fully independent entities, and each reported directly to the Board and/or the Compensation Committee, as appropriate. No services were provided by any of these firms other than the foregoing compensation consulting services. In no case did consulting fees approach or exceed \$120,000 for any of such firms in fiscal 2009.

**Table of Contents****Benchmarking**

In September 2009, the Compensation Committee, in coordination with Matthews Young, conducted an overall review of the Company's executive compensation program. As part of this review, the peer group of 18 banks used in the prior benchmarking analysis completed in September 2007 was analyzed and updated. Of the original peer group, one financial institution was no longer in operation and was replaced with a comparable peer. All peers in the current benchmark group remain comparable to the Company in terms of geographic location, asset size and market capitalization. The Company performed above the median (59<sup>th</sup> percentile) compared to peers on Return on Average Assets ( ROAA ) and Return on Average Equity ( ROAE ). The peer group is presented in the table below. Values reported in the table are as of June 30, 2009.

Company Name	Ticker	City	State	Total Assets (\$000)	Market Cap (\$M)	ROAA (%)	ROAE (%)
1 Bank of Florida Corporation	BOFL	Naples	FL	1,520,350	41	-1.71	-14.18
2 BancTrust Financial Group, Inc.	BTFG	Mobile	AL	2,074,654	56	-1.83	-23.31
3 Capital Bank Corporation	CBKN	Raleigh	NC	1,659,342	62	0.24	3.50
4 Capital City Bank Group, Inc.	CCBG	Tallahassee	FL	2,525,839	253	0.12	1.12
5 Fidelity Southern Corporation	LION	Atlanta	GA	1,894,908	30	-1.23	-18.23
6 First Bancorp	FBNC	Troy	NC	3,518,556	303	3.98	43.52
7 FNB United Corp.	FNBN	Asheboro	NC	2,199,606	27	-0.07	-0.84
8 Great Florida Bank	GFLB	Coral Gables	FL	1,740,559	19	-1.41	-17.91
9 Green Bankshares, Inc.	GRNB	Greenville	TN	2,629,834	79	-21.67	-157.41
10 NewBridge Bancorp	NBBC	Greensboro	NC	2,105,567	33	-1.13	-13.75
11 Pinnacle Financial Partners, Inc.	PNFP	Nashville	TN	5,036,742	517	-2.67	-20.52
12 SCBT Financial Corporation	SCBT	Columbia	SC	2,812,215	351	0.77	7.23
13 Seacoast Banking Corporation of Florida	SBCF	Stuart	FL	2,186,548	49	-2.34	-25.07
14 StellarOne Corporation(1)	STEL	Charlottesville	VA	3,056,915	293	-0.04	-0.33
15 Southern Community Financial Corporation	SCMF	Winston-Salem	NC	1,726,709	51	-0.59	-5.80
16 TIB Financial Corp.	TIBB	Naples	FL	1,797,081	28	-1.23	-16.72
17 Wilson Bank Holding Company	WBHC	Lebanon	TN	1,445,417	128	0.91	10.05
18 Yadkin Valley Financial Corporation	YAVY	Elkin	NC	1,637,082	89	-1.02	-11.27
Average				2,309,329	134	-1.69	-14.07
Maximum				5,036,742	517	3.98	43.52
50th Percentile				2,090,111	59	-0.86	-9.78
Minimum				1,445,417	19	-21.67	-157.41
<b>Ameris Bancorp</b>		<b>Value</b>		<b>2,118,243</b>	<b>89</b>	<b>-0.47</b>	<b>-4.62</b>
		<b>Percentile Rank</b>		<b>66<sup>th</sup></b>	<b>65<sup>th</sup></b>	<b>59<sup>th</sup></b>	<b>59<sup>th</sup></b>

(1) Replaced Security Bank Corporation (SBKC) due to the sale of SBKC.

**Table of Contents**

For each of our named executive officers, we selected peers with comparable titles and areas of responsibilities (e.g., matching the Company's Chief Financial Officer with the Chief Financial Officer position in each of the peer banks). The peer group comparison provided the primary market data upon which we determined the market standing of our executive compensation levels. The table below provides a summary of how each named executive officer was benchmarked to the Company's peers.

<u>Name</u>	<u>Title</u>	<u>Peer Comparison</u>
Edwin W. Hortman, Jr.	President and CEO	CEO
Dennis J. Zember Jr.	EVP and CFO	CFO
Andrew B. Cheney	EVP and Banking Group President	Chief Banking Officer
Marc J. Bogan	EVP and COO	Chief Retail and Operations Officer
Jon S. Edwards	EVP, SCO and Director of Credit Administration	Chief Credit Officer
C. Johnson Hipp, III	EVP and Banking Group President (Retired)	Chief Banking Officer

**Elements of Compensation**

Total direct compensation typically includes cash, in the form of base salary and annual incentives, and long-term equity incentives. The Compensation Committee evaluates the mix between these elements based on the pay practices of comparable companies. The Compensation Committee strives to be fully informed in its determination of the appropriate compensation mix and award levels for the named executive officers, including consideration of publicly available information and the retention of compensation consultants when deemed appropriate. The Compensation Committee's guiding principles of fairness to employees, retention of talented executives and fostering improved Company performance guide all of its compensation decisions. As a participant in TARP, the Company is required to adhere to specific parameters limiting the forms of compensation we provide and, in some cases, the levels of such compensation. With respect to the named executive officers, the elements of compensation used during 2009 include the following:

base salary;

long-term equity awards;

retirement benefits;

health and insurance benefits; and

perquisites.

Unlike prior years, we were unable to incorporate annual cash incentives linked to performance goals in our named executive officer compensation program in 2009. As discussed above, based upon our level of funding received, TARP regulations prohibit the use of this form of compensation for our top five most-highly compensated employees. Our grants of stock option awards were made prior to the adoption of TARP restrictions prohibiting stock option grants, and no further option grants were awarded to executive management after such limitations became effective.



## Edgar Filing: Symmetry Medical Inc. - Form 10-K

Under TARP regulations, the compensation requirements limiting the use of annual incentive pay and stock options applied only to our five most-highly compensated employees. To maintain a consistency and sense of fairness in our approach to compensation, we applied these TARP compensation limits to all of our executive management team. Following is a discussion of each element of compensation used in 2009 for our named executive officers, including the purpose of each element of compensation, why we elect to pay each element of compensation, how each element of compensation was determined by the Compensation Committee and how each element and our decisions regarding the payment of each element relate to our goals.

**Table of Contents**Base Salary

It is the Company's philosophy that employees be paid a base salary that is competitive with the salaries paid by comparable organizations based on each employee's experience, performance and any other unique factors or qualifications. Generally, the Company has chosen to position cash compensation at market median levels in order to remain competitive in attracting and retaining executive talent. The allocation of total cash compensation between base salary and annual bonus is based on a variety of factors. In addition to the market positioning of the base salary and the mix of total compensation, the Compensation Committee also takes into consideration the following:

the executive's performance;

the performance of the Company;

the performance of the individual business or corporate function for which the executive is responsible;

the nature and importance of the position and role within the Company;

the scope of the executive's responsibility; and

the current compensation package in place for that executive, including the executive's current annual salary and potential bonus awards under the Company's bonus plan.

In the following table, we summarize the changes in base compensation made during 2009. Due to the economic environment and the corresponding impact of the economy on the Company's performance, we offered no merit base salary increases to any of our named executive officers. Mr. Cheney, a newly hired employee on February 17, 2009, received a promotional increase to reflect his transition to the role of Executive Vice President and Banking Group President effective on May 26, 2009.

<u>Named Executive Officer</u>	<u>2008 Base Salary</u>	<u>2009 Base Salary</u>	<u>Merit Increase</u>	<u>Market Adjustment</u>	<u>Promotion Increase</u>	<u>Total Adjustment</u>
Edwin W. Hortman, Jr.	\$ 400,000	\$ 400,000	0.00%	0.00%	0.00%	0.00%
Dennis J. Zember Jr.	\$ 215,000	\$ 215,000	0.00%	0.00%	0.00%	0.00%
Andrew B. Cheney(1)	\$ 200,000	\$ 225,000	0.00%	0.00%	12.50%	12.50%
Marc J. Bogan	\$ 185,000	\$ 185,000	0.00%	0.00%	0.00%	0.00%
Jon S. Edwards	\$ 176,500	\$ 176,500	0.00%	0.00%	0.00%	0.00%
C. Johnson Hipp, III(2)	\$ 225,000	\$ 225,000	0.00%	0.00%	0.00%	0.00%
<b>Totals for All Named Executive Officers</b>	<b>\$ 1,401,500</b>	<b>\$ 1,426,500</b>				<b>1.78%</b>

(1) Mr. Cheney was hired on February 17, 2009 with an initial base salary of \$200,000. His salary was increased effective May 26, 2009 in connection with his transition to EVP and Banking Group President.

(2)

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

On May 5, 2009, Mr. Hipp was granted certain agreed-upon leave from his employment for medical reasons. He retired from the Company on December 31, 2009.

In response to the compensation limitations imposed upon TARP recipients, a number of companies have chosen to substantially increase base salaries or to provide additional base pay compensation in the form of salary stock. We chose in 2009 to keep our base salaries consistent with the prior year and have not pursued these courses of action to supplement base pay levels.

Based on the analysis and peer benchmarking conducted by Matthews Young, as well as the supplementary analysis conducted by Blanchard Chase, 2009 base salaries for all of our named executive officers fall within a range that is competitive with the market median ( $\pm 15\%$  of the market median). Salaries for each individual named executive officer ranged from  $-8\%$  to  $+14\%$ , with an overall average for the entire group of  $+3\%$  to market.

---

**Table of Contents**

Annual Incentives

Annual incentives are normally provided to the executive officers through the Company's Annual Incentive Compensation Plan (the "AIP"). Annual incentives are primarily designed to focus the executive officers on our goals for a particular year and to reward executive officers upon achievement of those goals. The Compensation Committee believes that a formalized plan, with specifically defined and clearly communicated goals, helps strengthen the link between pay and performance.

As a result of TARP restrictions, the named executive officers are ineligible to receive such performance-based annual incentive compensation. Although there was no opportunity to provide our named executive officers with performance-based incentive compensation during 2009, we strongly believe in the value of strategic planning and setting performance goals for our executive officers and all other employees.

The Compensation Committee considers both quantitative and qualitative factors in determining the performance goals and targets applicable to the executive officers. The Compensation Committee regularly weights the quantitative and qualitative factors differently for each executive officer in consideration of the specific responsibilities for each position.

In 2009, the Board believed the economic and operating challenges posed a higher level of risk to the Company than in past years. The higher level of risk was considered to be fiscal, reputational and cultural. Although a formalized weighting scheme was not applied to each goal, the Board generally gave equal consideration to both quantitative and qualitative goals when assessing named executive officer performance. With respect to the goals within the quantitative group, the Board considered goals related to capital and liquidity strength to be the most critical, followed by the improvement of the Company's risk profile. The Compensation Committee does not believe that 2009's goals or the weightings thereof are indicative of future actions or philosophy but instead a reasonable response to the economic and operating challenges of the most recently completed fiscal year.

The Compensation Committee considered the quantitative goals applicable to executive officers to be challenging and more difficult to achieve than in prior years due to the limited options available to management in the current economic environment. Such goals, to the extent they are measured over a multi-year time horizon, may continue to prove challenging for the executives to achieve in the absence of a broad, sustained rebound in the economy generally. The Compensation Committee's context for making these determinations included such factors as the following:

the Company's operating performance in 2008 relative to peers and to management's forecasts;

the Company's forecasts for 2009 with respect to net revenues and credit quality factors;

national and regional economic forecasts; and

the anticipated ineffectiveness of traditional approaches in managing the Company's operating performance, including access to capital markets, opportunities for asset and revenue growth and methods normally used to dispose of problem assets.

The Compensation Committee considered the qualitative goals more difficult to achieve than in recent years for the following reasons:

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

increased public scrutiny of the financial industry, particularly institutions that participated in TARP;

increased regulatory inquiry resulting from a growing number of bank failures and from Congressional pressures; and

increased risk of lower employee morale resulting from lower levels of compensation and the changes necessary to succeed in the current environment.

---

**Table of Contents**

Long-Term Equity Awards

The Compensation Committee believes there should be a significant equity-based component to executive compensation because this best aligns the executives' interests with those of the Company's shareholders. For purposes of retention, the Compensation Committee believes that the equity-based compensation should have meaningful conditions to encourage valued employees to remain with the Company.

The Company's officers and certain other employees may participate in the Company's shareholder-approved 2005 Omnibus Stock Ownership and Long-Term Incentive Plan (the 2005 Plan). The 2005 Plan document is set forth as *Appendix A* to the Company's Definitive Proxy Statement for the Company's 2005 annual meeting of shareholders. Awards may be granted under the 2005 Plan from time to time and may be in the form of qualified or nonqualified stock options, restricted stock, stock appreciation rights, long-term incentive compensation units consisting of a combination of cash and Common Stock or any combination thereof within the limitations set forth in the 2005 Plan. As discussed above, under current TARP regulations, as of February 11, 2009, the Company was limited to the use of restricted stock at a level not to exceed one-third of a named executive officer's total compensation for the year.

The 2005 Plan provides that awards may be made for 10 years from its effective date of March 10, 2005. The 2005 Plan is administered by the Compensation Committee, which selects eligible employees to participate in the 2005 Plan and determines the type, amount and duration of all individual awards. Prior to the adoption of the 2005 Plan, equity awards were granted pursuant to the ABC Bancorp Omnibus Stock Ownership and Long-Term Incentive Plan that was adopted in 1997 and which now is operative only with respect to the exercise of options that remain outstanding under such plan.

The Compensation Committee carefully considers the following factors when determining the type and amount of equity to award:

prior awards issued to the executive officer;

the current amount and intrinsic value of unvested equity held by the executive officer;

current number of shares owned by the executive officer;

proportion of total compensation on an annual basis consisting of equity awards;

market data on the median level of equity awarded to comparable positions; and

compliance with Treasury regulations applicable to TARP participants.

Equity awards provided to our named executive officers under the 2005 Plan have historically consisted of annual awards of incentive stock options, restricted stock grants or a blend of both. Vesting schedules applied to these awards ranged from three- to five-year periods. Between 2005 and 2007, all equity awards to our named executive officers were granted with performance conditions applied in addition to time-based requirements. The intent of applying performance vesting provisions was two-fold – first to increase the ability to drive performance with equity awards beyond the innate performance nature of equity, and second, to provide the Company with the ability to reverse the expense associated

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

with equity grants should performance goals fail to be achieved. The drawback of the approach is that performance-vesting on all equity awards leads to the possible risk of the officers holding no actively vesting awards and thereby leaving nothing of value behind should they choose to voluntarily resign from the organization. In such event, the equity grants lose all possible retention value.

In 2008, we awarded time-vested option awards to bring our compensation mix of short-term cash payments and long-term equity based compensation into alignment with our compensation philosophy and market competitiveness. In 2009, we continued our use of performance vesting option grants and restricted stock to maintain the balance of short-term and long-term compensation in our executive compensation programs. All such equity grants were made in compliance with TARP restrictions regarding the use of equity compensation.

## Table of Contents

The 2009 grants, with a mix of options vesting based on performance and time-vesting restricted stock, provide the Company with a balance between employee motivation and retention. The levels of the awards provided to each named executive officer were based on a compensation analysis conducted by Matthews Young and were targeted to provide equity levels comparable to peers at the market median for these positions. TARP requirements were adhered to with respect to the types of equity awards used and the amounts of equity granted.

In addition to the equity awards granted to our named executive officers, 2009 performance results impacted the vesting of prior awards granted with performance vesting provisions. As discussed above, the challenging economic climate provided few opportunities for improvement in quantitative performance measures from the standpoint of both the Company as a whole and each individual named executive officer.

### Perquisites

The Company provided a company card and club membership in 2009 to certain executive officers.

The aggregate cost of all perquisites for all of our named executive officers was approximately \$26,359. No individual named executive officer received a total value of perquisites in excess of \$12,400 during 2009. Additional details on perquisites are provided in a supplementary table to the Summary Compensation Table presented below.

We view certain perquisites as being beneficial to the Company, in addition to being directly compensatory to the executive officers. For example, the club memberships are regularly used in the general course of our business, such as for business meetings or entertaining. Company cars provided to executive officers are used primarily for business purposes. In addition, these perquisites, as a minor expense to the Company, provide a useful benefit in our efforts to recruit, attract and retain top executive talent.

### Retirement Benefits

We do not have a defined benefit pension plan or a nonqualified deferred compensation plan. However, executive officers are eligible to participate in our 401(k)/profit sharing retirement plan, which is a Company-wide, tax-qualified retirement plan. The intent of this plan is to provide all employees with a tax-advantaged savings opportunity for retirement. We sponsor this plan to help employees in all levels of the Company save and accumulate assets for use during their retirement. As required, eligible pay under this plan is capped at Internal Revenue Code annual limits. The Company offers a discretionary match to employee contributions based upon the performance of the Company and subject to the approval of the Board. Company contributions to the 401(k)/profit sharing plan vest in equal annual installments over a five-year period.

In addition, we also provide our employees with an employee stock purchase plan, which provides the employee with the opportunity to purchase shares of Common Stock via payroll deduction. The minimum purchase is \$50 and the plan does not provide discounts or look-back features. The plan covers the administrative costs involved in the purchase of the stock.

### Health and Welfare Plans



## Edgar Filing: Symmetry Medical Inc. - Form 10-K

The named executive officers are eligible to participate in Company-sponsored benefit plans on the same terms and conditions as those generally provided to salaried employees. Basic health benefits, dental benefits and similar programs are provided to make certain that access to healthcare and income protection is available to our employees and their family members. Health benefits also include a Section 125 plan or a health savings account to provide for pre-tax deferral for non-reimbursable health expenses. The cost of Company-sponsored benefit plans is negotiated with the providers of such benefits, and the executive officers contribute to the cost of the benefits.

**Table of Contents**

Total Compensation

The allocation of total compensation between base salary, annual bonus, long-term (equity) compensation and other compensation is based on a variety of factors. The Compensation Committee considers a combination of the executive's performance, the performance of the Company and the individual business or corporate function for which the executive is responsible, the nature and importance of the position and the executive's role within the Company. TARP constraints regarding the use of annual incentive compensation, stock options and the amount of restricted stock permissible for our named executive officers notably altered our mix of compensation elements for 2009.

In prior years, the Company incorporated a significant portion of the named executive officers' compensation in the form of annual incentives. The annual incentive plan provided a strong link between executive compensation and shareholder interests through the use of performance measures such as earnings per share. As discussed above, in 2009, as a result of TARP limitations, our compensation program consisted primarily of base salary and permissible levels of restricted stock awards. Annual cash incentives have been eliminated and stock option grants were limited, occurring prior to the effectiveness of TARP restrictions on stock option awards.

Between 2007 and 2008 total compensation levels remained flat and, in certain cases, decreased. This was due primarily to a lack of annual cash incentives earned during both 2007 and 2008, as well as to the limited number of equity awards that were made during that period. In 2009, as the Board approved equity grants to balance the mix of compensation between annual cash payments and long-term equity, there was an increase in total compensation for Messrs. Hortman, Zember and Bogan. The equity awards granted in 2009 vest over a three-year period, subject to TARP vesting limitations. Should the stock price of the Company decline over that timeframe, the values presented below will decrease notably for 2009, with a lesser impact on the 2007 and 2008 values presented.

As previously noted, cash compensation (the sum of base salary, cash bonus, annual cash incentives and other compensation) has remained generally flat over the past three years, with slight decreases in annual cash compensation during the three-year time period.

**Table of Contents**

The primary change in total compensation levels is attributable to an increase in the use of equity compensation over the past three years, primarily in the form of restricted stock.

**Table of Contents**

The following chart presents the actual pay mix results from 2007 through 2009 for each of our named executive officers. As discussed above, our compensation philosophy is to maintain a significant equity-based component to executive compensation because this best aligns the executives' interests with those of the Company's shareholders. For purposes of retention, the Compensation Committee believes that equity-based compensation should have meaningful conditions to encourage valued employees to remain with the Company. In 2009, the Compensation Committee awarded equity grants to realign our executive compensation levels with the Company's compensation philosophy and maintain market competitive levels of equity and total compensation.

**Table of Contents**

**Stock Ownership Requirements**

To further ensure that the long-term interests of the Company's senior management are aligned with those of the Company's shareholders, the named executive officers, as well as the Company's directors and other officers, are required by the Company's stock ownership guidelines to acquire and maintain a specified investment in the Company. Our current guidelines require our directors to own 7,500 shares of stock with a five year period provided to attain this level of ownership

We require our named executive officers to own stock with a market value equivalent to three times the executive's base salary. Newly hired or promoted executives will be provided a five-year time frame to meet this ownership requirement. The Board and the Corporate Governance and Nominating Committee reviewed existing guidelines on June 23, 2009. At that time, the Committee modified the existing guidelines to address the impact of stock price volatility in the current economic environment. On a going forward basis these guidelines will be review annually.

**Insider Trading Policy**

The Board has adopted an insider trading policy statement. The provisions of this policy expressly prohibit directors, officers or other employees from trading, either directly or indirectly, in securities of the Company after becoming aware of material nonpublic information related to the Company. To further ensure adherence with this policy, guidelines have been established for blackout periods and for appropriate disclosure of internal information to external parties. The insider trading policy provides guidance as to what constitutes material information and when information becomes public. The insider trading policy addresses transactions by family members and under Company plans, as well as other transactions which may be prohibited, such as short-term trading, short sales, publicly trading in options, hedging transactions, margin purchases and post-termination transactions. The policy discusses the consequences of an insider trading violation, additional trading restrictions and certain reporting requirements applicable to directors, officers and designated key employees. The policy requires all senior officers, including all named executive officers, to provide written certification of their understanding of, and intent to comply with, the policy.

**Policy on Stock Options Repricing**

Stock options are granted at the fair market value of a share of Common Stock on the date of grant and are not subject to repricing.

**Policy on Timing of Stock Option Awards**

The timing of stock awards under an established plan must be consistent with program guidelines. In every instance, the Board will approve any stock award prior to the granting of such an award. Stock option awards must be approved by the Board and should always be dated subsequent to the date of Board approval.

**Tax Deductibility of Executive Officer Compensation**

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

Section 162(m) of the Internal Revenue Code generally disallows a tax deduction to public companies for compensation over \$1 million paid to a corporation's Chief Executive Officer and the four other most highly compensated executive officers.

In connection with the compensation of our named executive officers, the Compensation Committee is aware of Section 162(m) as it relates to deductibility of qualifying compensation paid to our named executive officers. To date, this provision has had no effect on the Company because no officer of the Company has received \$1.0 million in applicable remuneration in any year. In addition, the Compensation Committee believes that compensation earned for 2008 does not exceed the deductibility limitations on non-excluded compensation to our named executive officers.

---

**Table of Contents**

TARP participants are subject to additional provisions under Section 162(m)(5) of the Internal Revenue Code which limit the deduction of compensation to \$500,000 per year for CEOs. Compensation covered by this limitation is more broadly defined than that for purposes of Section 162(m) generally and includes incentive compensation and deferred compensation. This provision applies to the Company throughout the TARP period. The Compensation Committee gives strong consideration to the deductibility of compensation in making its compensation decisions for executive officers, while balancing the goal of maintaining a compensation program that will enable the Company to attract and retain qualified executives with the goal of maximizing the creation of long-term shareholder value.

**Employment Agreements**

We currently maintain an employment agreement with each of our named executive officers. The employment agreements provide for the payment of severance to the executive officer upon a termination by the executive for good reason (as defined) in connection with a Change of Control (as defined). Payments are not provided with respect to other termination events. We do not maintain a separate severance plan for our executive officers. Severance benefits for our executive officers are limited to those set forth in the executive officer's employment agreement. We provide details on the estimated payments associated with a qualifying termination in connection with a Change of Control in the section of this Proxy Statement entitled Potential Payments Upon Termination or Change in Control .

Set forth below are the general terms and conditions of each employment agreement applicable to our named executive officers. Under current TARP regulations, no payment associated with a termination from employment may be provided to an CEO, and no acceleration of vesting may be applied to unvested equity held by an CEO upon termination of employment. In addition, the accrual or payment of annual incentives is also prohibited for these employees by TARP regulations. All of our named executive officers provided written acceptance of TARP restrictions applicable to the terms presented in the following agreements.

**General Agreement Provisions**

All agreements limit severance benefits to a termination of employment by the executive for good reason in association with a Change of Control and cap payments with respect to Section 280G of the Internal Revenue Code. The following summarizes the definition of good reason as set forth in the agreements:

a change in the executive's reporting responsibilities, titles or offices or any removal of the executive from, or any failure to re-elect the executive to, any of the executive's positions held which has the effect of diminishing the executive's authority or responsibility;

a reduction in base salary or change in bonus opportunity or incentive performance plan criteria adversely affecting the executive;

requiring the executive to relocate (either outside of the state or outside a 50-mile radius of current executive offices);

a failure to continue health, welfare and benefit plans without a replacement, or to reduce the existing benefits under such plans; or

adversely altering the physical conditions of the workplace.

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

Each agreement specifies term, position and duties, salary and bonus/incentive eligibility, benefits, perquisites, expense reimbursement and vacation. In addition, each agreement includes non-compete and non-solicit covenants. Details on the individual arrangements are set forth below.



**Table of Contents**

Individual Employment Agreement Provisions

*Edwin W. Hortman, Jr. Chief Executive Officer*

The Company entered into an executive employment agreement with Mr. Hortman effective as of December 31, 2003, as amended (the "Hortman Employment Agreement"), pursuant to which Mr. Hortman has agreed to serve as the President and Chief Executive Officer of the Company for a continuously (on a daily basis) renewing, three-year period until such time as either party gives written notice to the other party not to extend the term of the Hortman Employment Agreement beyond the date that is three years after the date specified in such notice. Notwithstanding any notice not to so extend, the term of the Hortman Employment Agreement will not expire prior to the expiration of 12 months after the occurrence of a Change of Control of the Company. The Hortman Employment Agreement, which automatically terminates when Mr. Hortman attains age 65, provides that Mr. Hortman will receive a minimum base salary of \$250,000. Mr. Hortman's base salary is currently \$400,000.

In addition, the Hortman Employment Agreement provides that Mr. Hortman is entitled to receive an annual bonus and to participate in all present and future employee benefit, retirement and compensation plans of the Company consistent with his salary and his position as the President and Chief Executive Officer of the Company. The Hortman Employment Agreement further provides that, in the event of termination of Mr. Hortman's employment with the Company, the Company will pay to Mr. Hortman his current base salary and annual bonus through the date of termination and, if he terminates his employment for "good reason" within 12 months after a Change of Control, his base salary and a bonus in an amount determined pursuant to the terms of the Hortman Employment Agreement for three additional 12-month periods.

Upon a termination of Mr. Hortman's employment under certain circumstances, Mr. Hortman will have the opportunity for a period of 90 days following the date of such termination to exercise all of his outstanding stock options at the exercise prices thereof. The Hortman Employment Agreement also includes certain restrictive covenants that limit Mr. Hortman's ability to compete with the Company for a period of one year after termination or divulge certain confidential information concerning the Company for a period of two years.

*Dennis J. Zember Jr. Chief Financial Officer*

The Company entered into an executive employment agreement with Mr. Zember effective as of May 6, 2005 (the "Zember Employment Agreement"), pursuant to which Mr. Zember has agreed to serve as Executive Vice President and Chief Financial Officer of the Company for an initial term of two years, which initial term is automatically renewed for additional consecutive two year terms unless timely notice of non-renewal is given by either the Company or Mr. Zember. Notwithstanding any notice not to so extend, the term of the Zember Employment Agreement will not expire prior to the expiration of 12 months after the occurrence of a Change of Control of the Company. The Zember Employment Agreement, which automatically terminates when Mr. Zember attains age 65, provides that Mr. Zember will receive a minimum base salary of \$182,500. Mr. Zember's base salary is currently \$215,000.

In addition, the Zember Employment Agreement provides that Mr. Zember is entitled to receive an annual bonus and to participate in all present and future employee benefit, retirement and compensation plans of the Company consistent with his salary and his position as the Chief Financial Officer of the Company. The Zember Employment Agreement further provides that, in the event of termination of Mr. Zember's employment with the Company, the Company will pay to Mr. Zember his base salary and annual bonus through the date of termination and, if he terminates his employment for "good reason" within 12 months after a Change of Control, his base salary and a bonus in an amount determined pursuant to the terms of the Zember Employment Agreement for two additional 12-month periods.

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

Upon a termination of Mr. Zember's employment for good reason, Mr. Zember will have the opportunity for a period of 90 days following the date of such termination to exercise all of his outstanding stock options at the

**Table of Contents**

exercise prices thereof. The Zember Employment Agreement also includes certain restrictive covenants that limit Mr. Zember's ability to compete with the Company for a period of one year after termination or divulge certain confidential information concerning the Company for a period of two years.

*Andrew B. Cheney Executive Vice President and Banking Group President*

The Company entered into an executive employment agreement with Mr. Cheney effective as of February 8, 2009 (the Cheney Employment Agreement), pursuant to which Mr. Cheney has agreed to serve as Executive Vice President for Florida and Coastal Georgia. Since the execution of the Cheney Employment Agreement, Mr. Cheney received a promotion to Executive Vice President and Banking Group President of the Company. The Cheney Employment Agreement has an initial term of two years, which initial term is automatically renewed for an additional 18-month term with consecutive one-year term renewals implemented after August 18, 2012. Such renewals will occur unless timely notice of non-renewal is given by either the Company or Mr. Cheney. Notwithstanding any notice not to so extend, the term of the Cheney Employment Agreement will not expire prior to the expiration of 12 months after the occurrence of a Change of Control of the Company. The Cheney Employment Agreement provides that Mr. Cheney will receive a minimum base salary of \$200,000. Mr. Cheney's base salary is currently \$225,000.

In addition, the Cheney Employment Agreement provides that Mr. Cheney is entitled to receive an annual bonus and to participate in all present and future employee benefit, retirement and compensation plans of the Company consistent with his salary and his position as Executive Vice President and Banking Group President of the Company. The Cheney Employment Agreement further provides that, in the event of termination of Mr. Cheney's employment with the Company, the Company will pay to Mr. Cheney his base salary and annual bonus through the date of termination and, if he terminates his employment for good reason within 12 months after a Change of Control, his base salary and a bonus in an amount determined pursuant to the terms of the Cheney Employment Agreement for one additional 12-month period.

Upon a termination of Mr. Cheney's employment under certain circumstances, Mr. Cheney will have the opportunity for a period of 90 days following the date of such termination to exercise all of his outstanding stock options at the exercise prices thereof. The Cheney Employment Agreement also includes certain restrictive covenants that limit Mr. Cheney's ability to compete with the Company for a period of one year after termination or divulge certain confidential information concerning the Company for a period of two years.

*Marc J. Bogan Executive Vice President and Chief Operating Officer*

The Company entered into an executive employment agreement with Mr. Bogan effective as of May 31, 2007 (the Bogan Employment Agreement), pursuant to which Mr. Bogan serves as the Executive Vice President and Chief Operating Officer of the Company (per Amendment 1 effective December, 30, 2008). The Bogan Employment Agreement has an initial term of one year, which initial term is automatically renewed for additional consecutive one-year terms unless timely notice of nonrenewal is given by either the Company or Mr. Bogan. Notwithstanding any notice not to so extend, the term of the Bogan Employment Agreement will not expire prior to the expiration of 12 months after the occurrence of a Change of Control of the Company. The Bogan Employment Agreement, which automatically terminates when Mr. Bogan attains age 65, provides that Mr. Bogan will receive a minimum base salary of \$142,500. Mr. Bogan's base salary is currently \$185,000.

In addition, the Bogan Employment Agreement provides that Mr. Bogan is entitled to receive an annual bonus and to participate in all present and future employee benefit, retirement and compensation plans of the Company consistent with his salary and his position as the Executive Vice President and Chief Operating Officer of the Company. The Bogan Employment Agreement further provides that, in the event of termination of Mr. Bogan's employment with the Company, the Company will pay to Mr. Bogan his base salary and annual bonus through the

Edgar Filing: Symmetry Medical Inc. - Form 10-K

date of termination and, if he terminates his employment for good reason within 12 months

**Table of Contents**

after a Change of Control, his base salary and a bonus in an amount determined pursuant to the terms of the Bogan Employment Agreement for one additional 12-month period.

Upon a termination of Mr. Bogan's employment for good reason, Mr. Bogan will have the opportunity for a period of 90 days following the date of such termination to exercise all of his outstanding stock options at the exercise prices thereof. The Bogan Employment Agreement also includes certain restrictive covenants that limit Mr. Bogan's ability to compete with the Company or divulge certain confidential information concerning the Company for a period of one year.

*Jon S. Edwards Executive Vice President and Director of Credit Administration*

The Company entered into an executive employment agreement with Mr. Edwards effective as of July 1, 2003 (the Edwards Employment Agreement), pursuant to which Mr. Edwards serves as the Executive Vice President and Director of Credit Administration of the Company. The Edwards Employment Agreement has an initial term of one year, which initial term is automatically renewed for additional consecutive one-year terms unless timely notice of nonrenewal is given by either the Company or Mr. Edwards. Notwithstanding any notice not to so extend, the term of the Edwards Employment Agreement will not expire prior to the expiration of 12 months after the occurrence of a Change of Control of the Company. The Edwards Employment Agreement, which automatically terminates when Mr. Edwards attains age 65, provides that Mr. Edwards will receive a minimum base salary of \$142,500. Mr. Edwards' base salary is currently \$176,500.

In addition, the Edwards Employment Agreement provides that Mr. Edwards is entitled to receive an annual bonus and to participate in all present and future employee benefit, retirement and compensation plans of the Company consistent with his salary and his position as the Executive Vice President and Director of Credit Administration of the Company.

The Edwards Employment Agreement further provides that, in the event of termination of Mr. Edwards's employment with the Company, the Company will pay to Mr. Edwards his base salary and annual bonus through the date of termination and, if he terminates his employment for good reason within 12 months after a Change of Control, his base salary and a bonus in an amount determined pursuant to the terms of the Edwards Employment Agreement for one additional 12-month period.

Upon a termination of Mr. Edwards's employment for good reason, Mr. Edwards will have the opportunity for a period of 90 days following the date of such termination to exercise all of his outstanding stock options at the exercise prices thereof. The Edwards Employment Agreement also includes certain restrictive covenants that limit Mr. Edwards' ability to compete with the Company for a period of up to two years after termination or divulge certain confidential information concerning the Company for a period of two years.

**COMPENSATION COMMITTEE REPORT**

The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis contained in this Proxy Statement with the Company's management and, based on such review and discussions, has recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement.

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

The Compensation Committee has concluded, through a comprehensive risk assessment, that the compensation programs and practices at the Company do not encourage employees, including the named executive officers, to take unnecessary and excessive risks that would threaten the value of the Company. The risk assessment included various discussions, review and evaluation of the Company's compensation plans and practices.

**Table of Contents**

The risk assessment included reviews of the following: (i) the various elements of compensation and the appropriate mix of such elements; (ii) applicable performance metrics to ensure that each plan's performance metrics do not focus solely on short-term results; (iii) performance goals and payout curves to ensure that each plan's goals and payouts are consistent with industry standards; (iv) the amount and type of any equity incentives to ensure that such grants were appropriate; and (v) the performance appraisal process to ensure that excessive emphasis is not placed on short-term or quantitative achievements.

Risk features have been limited in the compensation plans for the Company's named executive officers by the addition of non-financial performance measures. Items such as acceptable examination results, acceptable asset quality measures and acceptable implementation of strategic objectives help to ensure that the named executive officers have a long-term view and that manipulation of earnings would not enhance their compensation.

The Compensation Committee certifies that: (i) it has reviewed with senior risk officers the senior executive officer compensation plans and has made all reasonable efforts to ensure that these plans do not encourage senior executive officers to take unnecessary and excessive risks that threaten the value of the Company; (ii) it has reviewed with senior risk officers the employee compensation plans and has made all reasonable efforts to limit any unnecessary risks these plans pose to the Company; and (iii) it has reviewed the employee compensation plans to eliminate any features of these plans that would encourage the manipulation of reported earnings of the Company to enhance the compensation of any employee.

Submitted by the Compensation Committee:

J. Raymond Fulp (Chairman)

Daniel B. Jeter

Jimmy D. Veal

**Table of Contents****SUMMARY COMPENSATION AND OTHER TABLES****Summary Compensation Table**

The Summary Compensation Table below sets forth the total compensation awarded to, earned by or paid to our named executive officers for 2007, 2008 and 2009.

Name and Principal Position	Year	Salary	Bonus	Stock Awards(1)	Option Awards(2)	Non-Equity Incentive Plan Compensation	Change in Pension Value and Nonqualified Deferred Compensation Earnings	All Other Comp(5)	Total
Edwin W. Hortman, Jr., President and Chief Executive Officer	2009	\$ 400,000	\$ 0	\$ 195,575	\$ 29,250	\$ 0	\$ 0	\$ 31,595	\$ 656,420
	2008	\$ 400,000	\$ 0	\$ 0	\$ 85,250	\$ 0	\$ 0	\$ 48,166	\$ 533,416
Dennis J. Zember Jr., Executive Vice President and Chief Financial Officer	2009	\$ 215,000	\$ 0	\$ 112,165	\$ 29,250	\$ 0	\$ 0	\$ 5,654	\$ 362,069
	2008	\$ 215,000	\$ 0	\$ 0	\$ 25,575	\$ 0	\$ 0	\$ 14,466	\$ 255,041
Andrew B. Cheney, Executive Vice President and Banking Group President(3)	2009	\$ 185,096	\$ 0	\$ 92,465	\$ 14,800	\$ 0	\$ 0	\$ 19,450	\$ 311,811
	2008	\$ 185,000	\$ 0	\$ 47,510	\$ 11,700	\$ 0	\$ 0	\$ 9,047	\$ 253,257
Marc J. Bogan, Executive Vice President and Chief Operating Officer	2009	\$ 177,400	\$ 0	\$ 0	\$ 25,575	\$ 0	\$ 0	\$ 21,833	\$ 224,808
	2007	\$ 160,417	\$ 0	\$ 0	\$ 43,920	\$ 32,083	\$ 0	\$ 20,264	\$ 241,684
Jon S. Edwards, Executive Vice President and Director of Credit Administration	2009	\$ 176,500	\$ 0	\$ 32,150	\$ 0	\$ 0	\$ 0	\$ 3,806	\$ 212,456
	2008	\$ 176,188	\$ 0	\$ 0	\$ 17,050	\$ 0	\$ 0	\$ 12,505	\$ 205,743
C. Johnson Hipp, III, Executive Vice President and Banking Group President Retired(4)	2009	\$ 165,963	\$ 0	\$ 0	\$ 43,920	\$ 0	\$ 0	\$ 21,046	\$ 230,929
	2009	\$ 225,000	\$ 0	\$ 57,600	\$ 0	\$ 0	\$ 0	\$ 9,782	\$ 292,382
	2008	\$ 225,000	\$ 0	\$ 0	\$ 51,150	\$ 0	\$ 0	\$ 27,253	\$ 303,403
	2007	\$ 220,833	\$ 0	\$ 0	\$ 54,900	\$ 0	\$ 0	\$ 18,179	\$ 293,912

- (1) Represents the aggregate grant date fair values of the awards. Grants were made in the form of restricted stock, with the awards for Messrs. Hortman, Zember, Bogan and Edwards fully vesting after a three-year period. Certain awards for Mr. Cheney vest over a five-year period with performance criteria applied to vesting. Awards made after June 15, 2009 are subject to additional vesting restrictions under TARP. See the Grants of Plan Based Awards table for more detail on vesting.
- (2) Represents the aggregate grant date fair values of the awards. Option awards were granted on January 20, 2009 for Messrs. Hortman, Zember, and Bogan with a Black-Scholes value of \$1.95 per option. Option awards were granted on February 17, 2009 for Mr. Cheney with a Black-Scholes value of \$1.48 per option. Options vest over a five-year period based upon annually established performance criteria determined for each named executive officer at the beginning of the applicable fiscal year. Assumptions used in the Black-Scholes valuation model to calculate fair market value are provided in Note 15 to the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2009.
- (3)



## Edgar Filing: Symmetry Medical Inc. - Form 10-K

Mr. Cheney was hired on February 17, 2009. All compensation data provided represents amounts earned and awarded based upon his partial year of employment.

(4) Mr. Hipp retired from the Company effective December 31, 2009.

(5) Details on the amounts reported for All Other Compensation in 2009 are set forth in the following supplementary table:

**Table of Contents****Details on All Other Compensation Reported in the Summary Compensation Table for 2009**

Named Executive Officer	Auto Provision(a)	Country Club/ Membership and Dues	Director Fees(b)	Dividends on Restricted Common Stock	Employer 401(k) Match	Life Insurance
Edwin W. Hortman, Jr.	\$ 664	\$ 1,931	\$ 18,496	\$ 2,602	\$ 7,350	\$ 552
Dennis J. Zember Jr.		\$ 4,234		\$ 1,204	\$ 0	\$ 216
Andrew B. Cheney	\$ 1,484	\$ 10,914		\$ 1,004	\$ 4,938	\$ 1,110
Marc J. Bogan	\$ 3,299	\$ 852		\$ 423	\$ 4,163	\$ 310
Jon S. Edwards		\$ 2,531		\$ 33	\$ 882	\$ 360
C. Johnson Hipp, III		\$ 450		\$ 1,550	\$ 6,750	\$ 1,032

(a) Amounts reported in the table reflect the personal-use levels of this perquisite.

(b) Reflects annual cash fees for board service. Additional information regarding fees provided for board responsibilities is set forth in the section of this Proxy Statement entitled Compensation of Directors.

**Grants of Plan-Based Awards**

The Grants of Plan-Based Awards Table below sets forth the target annual incentive opportunity under non-equity incentive plans, as well as the total number of equity awards granted in 2009. The Grants of Plan-Based Awards Table should be read in conjunction with the Summary Compensation Table. As discussed above, under rules applicable to TARP recipients, the Company is prohibited from the payment or accrual of incentive compensation, including the use of stock options, for the top five most-highly compensated employees during the TARP period. In addition, the use of restricted stock grants is limited to no greater than one-third of the total compensation of these employees. The following data reflects both our continued emphasis on using plan-based awards to align management compensation with shareholder value and to maintain compliance with TARP requirements.

Name	Grant Date	Estimated Future Payouts Under Non-Equity Incentive Plan Awards			Estimated Future Payouts Under Equity Incentive Plan Awards			All Other Stock Awards: Number of Shares of Stock or Units	All Other Option Awards: Number of Securities Underlying Options (#)	Exercise or Base Price of Option Awards (\$/Sh)	Grant Date Fair Value of Stock and Option Awards(1)
		Threshold (\$)	Target (\$)	Max (\$)	Threshold (#)	Target (#)	Max (#)				
Edwin W. Hortman, Jr.	1/20/2009					15,000				\$ 7.68	\$ 29,250
	1/20/2009							15,000			\$ 115,200
	11/25/2009							12,500			\$ 80,375
Dennis J. Zember Jr.	1/20/2009					15,000				\$ 7.68	\$ 29,250
	1/20/2009							10,000			\$ 76,800
	11/25/2009							5,500			\$ 35,365
Andrew B. Cheney	2/17/2009					10,000				\$ 5.71	\$ 14,800
	2/17/2009					10,000					\$ 57,100
	11/25/2009							5,500			\$ 35,365

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

Marc J. Bogan	1/20/2009	6,000		\$ 7.68	\$ 11,700
	1/20/2009		2,000		\$ 15,360
	11/25/2009		5,000		\$ 32,150
Jon S. Edwards	11/25/2009		5,000		\$ 32,150
C. Johnson Hipp, III	1/20/2009		7,500	\$ 7.68	\$ 57,600

- (1) Amounts granted pursuant to the Company's 2005 Omnibus Stock Ownership and Long-Term Incentive Plan as described in the Compensation Discussion and Analysis included in this Proxy Statement. Assumptions used to calculate fair market value are provided in Note 15 to the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009. The Black-Scholes calculation resulted in a \$1.95 fair market value per share for awards granted on January 20, 2009 and a \$1.48 fair market value per share for awards granted on February 17, 2009.

**Table of Contents**

**Outstanding Equity Awards at Fiscal Year-End**

The Outstanding Equity Awards at Fiscal Year-End Table below reflects each named executive officer's unexercised option award holdings at December 31, 2009 on an individual award basis. The value of stock awards is based on \$7.16, the reported closing price of one share of Common Stock on December 31, 2009.

Name	Options Awards					Stock Awards				
	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Equity Incentive Plan Awards Number of Securities Underlying Unexercised Options (#)	Options Exercise Price	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Rights That Have Not Vested (#)	Equity Incentive Plan Awards: Market Payout Value of Unearned Shares, Units or Rights That Have Not Vested	Date Equity Fully Vests <sup>(12)</sup>
Edwin W. Hortman, Jr.	1,219	0	0	\$ 8.62	1/16/2011					
	2,437	0	0	\$ 11.94	7/16/2012					
	3,656	0	0	\$ 13.54	8/19/2013					
	4,874	0	0	\$ 15.49	5/18/2014					
	7,514	0	11,272	\$ 17.72	6/28/2015					1/31/2010 <sup>(1)</sup>
	8,124	0	12,185	\$ 22.51	6/13/2017					1/31/2012 <sup>(2)</sup>
	0	25,386	0	\$ 14.95	2/19/2018					2/19/2011 <sup>(3)</sup>
	0	0	15,232	\$ 7.56	1/20/2019					1/31/2014 <sup>(4)</sup>
					15,000	\$ 107,400			1/20/2012 <sup>(5)</sup>	
					12,500	\$ 89,500			11/25/2012 <sup>(6)</sup>	
Dennis J. Zember Jr.	7,311	4,874	0	\$ 16.45	2/15/2015					2/15/2010 <sup>(7)</sup>
	5,077	0	7,616	\$ 17.72	6/28/2015					1/31/2010 <sup>(1)</sup>
	508	0	2,031	\$ 20.44	5/16/2016					1/31/2011 <sup>(8)</sup>
	4,874	0	7,311	\$ 22.51	6/13/2017					1/31/2012 <sup>(2)</sup>
	0	7,616	0	\$ 14.95	2/19/2018					2/19/2011 <sup>(3)</sup>
	0	0	15,232	\$ 7.56	1/20/2019					1/31/2014 <sup>(4)</sup>
					10,000	\$ 71,600			1/20/2012 <sup>(5)</sup>	
					5,500	\$ 39,380			11/25/2012 <sup>(6)</sup>	
Andrew B. Cheney	0	0	10,154	\$ 5.62	2/17/2019			10,000	\$ 71,600	1/31/2014 <sup>(4)</sup>
										1/31/2014 <sup>(4)</sup>
					5,500	\$ 39,380				11/25/2012 <sup>(6)</sup>
Marc J. Bogan	2,031	0	3,046	\$ 25.77	9/19/2016					1/10/2012 <sup>(9)</sup>
	3,249	0	4,875	\$ 22.51	6/13/2017					1/31/2012 <sup>(2)</sup>
	0	7,616	0	\$ 14.95	2/19/2018					2/19/2011 <sup>(3)</sup>
	0	0	6,093	\$ 7.56	1/20/2019			1,200	\$ 8,592	1/10/2012 <sup>(10)</sup>
						2,000	\$ 14,320			1/31/2014 <sup>(4)</sup>
					5,000	\$ 35,800			1/20/2012 <sup>(5)</sup>	
									11/25/2012 <sup>(6)</sup>	
Jon S. Edwards	4,874	0	0	\$ 8.52	1/18/2010					

Edgar Filing: Symmetry Medical Inc. - Form 10-K

	3,656	0	0	\$ 8.62	1/16/2011	
	3,656	0	0	\$ 11.94	7/16/2012	
	3,656	0	0	\$ 13.54	8/19/2013	
	1,828	0	0	\$ 15.49	5/18/2014	
	2,031	0	3,046	\$ 17.72	6/28/2015	1/31/2010 <sup>(1)</sup>
	812	0	3,250	\$ 20.44	5/16/2016	1/31/2011 <sup>(8)</sup>
	3,249	0	4,875	\$ 22.51	6/13/2017	1/31/2012 <sup>(2)</sup>
	0	5,077	0	\$ 14.95	2/19/2018	2/19/2011 <sup>(3)</sup>
						5,000 \$ 35,800
						11/25/2012 <sup>(6)</sup>
C. Johnson Hipp, III <sup>(11)</sup>	4,062	0	6,092	\$ 22.51	6/13/2017	1/31/2012 <sup>(2)</sup>
	0	15,232	0	\$ 14.95	2/19/2018	2/19/2011 <sup>(3)</sup>
						7,500 \$ 53,700
						11/25/2012 <sup>(6)</sup>

(1) Options vest in five equal installments with the initial tranche vesting on January 31, 2006 based on the achievement of an established performance goal for fiscal 2005. Additional tranches vest on each following twelve-month anniversary based on the achievement of

**Table of Contents**

established performance goals for the most recently-completed fiscal year prior to that date. Should any single year fail to vest due to a failure to meet the performance goal for that year, the foregoing award may vest in the final year if the final year's goal is attained.

- (2) Options vest in five equal installments with the initial tranche vesting on January 31, 2008 based on the achievement of established performance goals for fiscal 2007. Additional tranches vest on each following twelve-month anniversary based on the achievement of established performance goals for the most recently-completed fiscal year prior to that date. Performance goals for each tranche will be set by the Board and will consist of both quantitative and qualitative criteria customized to the employee. Should any single year fail to vest due to a failure to meet the performance goal for that year, the foregoing award may vest in the final year if the final year's goal is attained.
- (3) Options vest 100% at the end of a three-year period.
- (4) Options or restricted shares vest in five equal installments with the initial tranche vesting on January 31, 2010 based on the achievement of established performance goals for fiscal 2009. Additional tranches vest on each following twelve-month anniversary based on the achievement of established performance goals for the most recently-completed fiscal year prior to that date. Performance goals for each tranche will be set by the Board and will consist of both quantitative and qualitative criteria customized to the employee.
- (5) Restricted stock fully vests after three years.
- (6) Restricted stock fully vests after three years. This award is subject to TARP restrictions in addition to the time-based vesting applied. For further details, see discussion of TARP restrictions on vesting provisions presented in the Compensation Discussion and Analysis included in this Proxy Statement.
- (7) Options vest in equal annual installments over a five-year period.
- (8) Options vest in five equal installments with the initial tranche vesting on January 31, 2007 based on the achievement of an established performance goal for fiscal 2006. Additional tranches vest on each following twelve-month anniversary based on the achievement of established performance goals for the most recently-completed fiscal year prior to that date. Should any single year fail to vest due to a failure to meet the performance goal for that year, the foregoing award may vest in the final year if the final year's goal is attained.
- (9) Options vest in five equal installments with the initial tranche vesting on January 10, 2008 based on the achievement of established performance goals for fiscal 2007. Additional tranches vest on each following twelve-month anniversary based on the achievement of established performance goals for the most recently-completed fiscal year prior to that date.
- (10) Restricted shares vest in five equal installments with the initial tranche vesting on January 10, 2008 based on the achievement of established performance goals for fiscal 2007. Additional tranches vest on each following twelve-month anniversary based on the achievement of established performance goals for the most recently-completed fiscal year prior to that date.
- (11) Mr. Hipp voluntarily retired from the Company on December 31, 2009. All outstanding and unvested equity awards held by Mr. Hipp were forfeited following his retirement.
- (12) All restricted stock awards may not fully vest while the Company is a TARP participant. For each 25% of TARP funds repaid by the Company, 25% of the shares may become transferable. Shares may be made transferable to pay federal, state and local income taxes due to the vesting of shares. In addition, an employee must forfeit restricted stock if the employee does not continue to perform substantial services for at least two years from the date of grant, other than on account of death, disability or a change-in-control event.

**Option Exercises and Stock Vested**

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

The Option Exercises and Stock Vested Table below reflects stock options actually exercised by each of our named executive officers during 2009 and restricted stock vesting during fiscal year 2009.

Name	Option Awards		Stock Awards	
	Number of Shares Acquired on Exercise (#)	Value Realized upon Exercise	Number of Shares Acquired on Vesting (#)	Value Realized on Vesting
C. Johnson Hipp, III			8,000	\$ 62,600 <sup>(1)</sup>

(1) Reflects the sum of 2,000 shares at the closing price of \$10.72 for one share of Common Stock on January 9, 2009 and 6,000 shares at the closing price of \$6.86 for one share of Common Stock on May 4, 2009.

### Pension Benefits

The Company does not provide pension benefits to our named executive officers.

---

**Table of Contents**

**Nonqualified Deferred Compensation**

The Company does not provide nonqualified deferred compensation to our named executive officers.

**Potential Payments Upon Termination or Change in Control**

The following discussion presents the potential payments for each named executive officer upon termination or change in control. Pursuant to applicable SEC rules, the analysis contained in this discussion does not consider or include payments made to a named executive officer with respect to contracts, agreements, plans or arrangements to the extent they do not discriminate in scope, terms or operation in favor of executive officers of the Company and that are available generally to all salaried employees. The actual amounts that would be paid upon a named executive officer's termination of employment can only be determined at the time of such executive officer's termination. Due to the number of factors that affect the nature and amount of any compensation or benefits provided upon the termination events, any actual amounts paid or distributed may be higher or lower than reported below. None of the payments estimated below may be made as presented during the TARP period. Among other factors that could affect these amounts are the timing during the year of any such event and our stock price.

In accordance with applicable SEC rules, the following discussion assumes that: (i) the termination event in question occurred on December 31, 2009; and (ii) with respect to calculations based on our stock price, the applicable price is \$7.16, which is the reported closing price of one share of Common Stock on December 31, 2009.

Each of the employment agreements between the Company and the named executive officers requires the Company to make severance payments and provide severance benefits to the executive if he terminates his employment with the Company for good reason within 12 months after the date of a Change of Control and in certain cases beyond 12 months after such an event. There are no severance payments otherwise required, including in connection with any of the following termination events;

voluntary termination/early retirement;

involuntary termination for Cause (as defined);

termination due to disability; or

termination due to death.

For these purposes, good reason is generally defined to mean that the executive has determined in good faith that one or more of the following events has occurred following or in anticipation of a Change of Control:

a change in the executive's reporting responsibilities, titles or offices, which has the effect of diminishing the executive's responsibility or authority;



## Edgar Filing: Symmetry Medical Inc. - Form 10-K

a reduction in the executive's salary or a change in the eligibility requirements or performance criteria under any bonus, incentive or compensation plan which adversely affects the executive;

the executive is required to relocate outside a 50-mile radius of Moultrie, Georgia (or in the case of Mr. Edwards, he is required to relocate outside the State of Georgia);

the Company's discontinuance of any pension, bonus, incentive, stock ownership, purchase, option, life insurance, health, accident, disability or other benefit plan in which the executive is participating or any other action by the Company that would adversely affect the executive's participation or materially reduce his benefits under any such plan; or

the taking of any action by the Company that would materially adversely affect the physical conditions under which the executive performs his employment duties.

---

**Table of Contents**

A Change of Control occurs under the employment agreements with the named executive officers if:

a majority of the Board becomes persons other than persons for whose election proxies shall have been solicited by the Board or who are then serving as directors appointed by the Board to fill vacancies caused by death, resignation or the creation of new directorships;

25% of the outstanding voting power of the Company is acquired or becomes beneficially owned by any person or by any two or more persons acting as a partnership, syndicate or other group acting in concert for the purpose of acquiring, holding or disposing of any voting stock of the Company, which group does not include the executive; or

there occurs:

a merger or consolidation of the Company with or into another corporation (other than a transaction with a subsidiary of the Company or a transaction in which (a) the holders of voting stock of the Company immediately prior to the merger continue to hold immediately after the merger at least a majority of all outstanding voting power of the surviving or resulting corporation or its parent and (b) all holders of each outstanding class or series of voting stock of the Company immediately prior to the merger or consolidation have the right to receive substantially the same cash, securities or other property in exchange for their voting stock of the Company as all other holders of such class or series);

a statutory exchange of shares of one or more classes or series of outstanding voting stock of the Company for cash, securities or other property;

the sale or other disposition of all or substantially all of the assets of the Company; or

the liquidation or dissolution of the Company;

unless, in each case, 25% or more of the voting equity of the surviving corporation or the corporation or other entity acquiring all or substantially all of the assets of the Company (in the case of a merger, consolidation or disposition of assets) or of the Company or its resulting parent corporation (in the case of a statutory share exchange) is beneficially owned by the executive or a group that includes the executive.

If a named executive officer terminates his employment for good reason within 12 months after the date of a Change of Control, then the executive will receive the following:

one additional year of current base salary (or three years in the case of Mr. Hortman and two years in the case of Mr. Zember), plus a bonus/incentive payment (which in the case of Messrs. Hortman, Zember and Edwards will not be less than 40% of the salary payable to such executive upon termination), payable in accordance with the Company's standard payment practices;

continued participation for one year (or three years in the case of Mr. Hortman and two years in the case of Mr. Zember) in the employee welfare benefit plans in which he was entitled to participate prior to termination;

continued Company contributions for one year at the maximum amount allowable under its 401(k) plan for the benefit of the executive (such contribution to be made for a period of two years in the case of Mr. Zember); and

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

in the case of Messrs. Hortman, Zember and Edwards, the executive will receive payment from the Company for reasonable relocation expenses if the executive relocates within 500 miles of Moultrie, Georgia and the relocation occurs within 180 days after the date of termination.

In addition, under each named executive officer's employment agreement, the executive will be entitled, for a period of 90 days after termination, to purchase all of the stock of the Company that would be issuable under all outstanding stock options previously granted to the executive, at the exercise prices set forth in such options,

**Table of Contents**

whether or not such options otherwise are then exercisable. The 2005 Plan also provides that in such event the executive's equity awards will become fully vested and, in the case of options, fully exercisable.

The foregoing payments and benefits are subject to reduction under the named executive officers' employment agreements in connection with certain tax matters. Those agreements provide that if the severance and change of control benefits payable to the executive would be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code, or would be nondeductible to the Company pursuant to Section 280G of the Internal Revenue Code, then such benefit payments shall be reduced to be the largest amounts that will result in no portion of the benefit payments being subject to the tax imposed by Section 4999 of the Internal Revenue Code or nondeductible by the Company. As required by

Section 409A of the Internal Revenue Code, all of the named executive officers' employment agreements have been modified to be in compliance with payment timing and other relevant requirements.

The estimated severance benefits payable to each of the named executive officers, based upon a hypothetical termination of the named executive officers on December 31, 2009 for good reason within 12 months following a Change of Control, are presented in the following table. The amounts include cash, equity, welfare benefits and retirement benefits. In addition, the table below presents the impact of limitations under Section 280G of the Internal Revenue Code and those arising as a result our participation in TARP. As shown in the table, under current TARP limitations, the named executive officers would be ineligible to receive any of these estimated post-termination payments.

Compensation or Benefits Payable	Edwin W. Hortman, Jr.	Dennis J. Zember Jr.	Andrew B. Cheney	Marc J. Bogan	Jon S. Edwards
<b>Compensation</b>					
Base Compensation	\$ 1,200,000	\$ 430,000	\$ 225,000	\$ 185,000	\$ 176,500
Annual Incentive	\$ 480,000	\$ 172,000	\$ 36,000	\$ 29,600	\$ 70,600
Intrinsic Value of Unvested Stock Options(1)	\$ 0	\$ 0	\$ 15,618	\$ 0	\$ 0
Intrinsic Value of Unvested Restricted Stock(1)	\$ 196,900	\$ 196,900	\$ 110,980	\$ 55,848	\$ 35,800
<b>Benefits and Perquisites</b>					
Health and Welfare Benefits(2)	\$ 27,193	\$ 16,077	\$ 11,013	\$ 6,201	\$ 6,110
401(k)/Profit Sharing Plan Contributions(3)	\$ 22,050	\$ 12,900	\$ 6,750	\$ 5,550	\$ 5,295
Relocation Expenses(4)	\$ 20,000	\$ 20,000	\$ 0	\$ 0	\$ 20,000
<b>Total Benefit</b>	<b>\$ 1,946,143</b>	<b>\$ 847,877</b>	<b>\$ 405,361</b>	<b>\$ 282,199</b>	<b>\$ 314,305</b>
<b>Total Benefit Provided Under 280G Cap(5)</b>	<b>\$ 1,605,929</b>	<b>\$ 847,877</b>	<b>\$ 405,361</b>	<b>\$ 282,199</b>	<b>\$ 314,305</b>
<b>Total Benefit Payable While a TARP Participant(6)</b>	<b>\$ 0</b>	<b>\$ 0</b>	<b>\$ 0</b>	<b>\$ 0</b>	<b>\$ 0</b>

- (1) The intrinsic value of equity is based on a share price of \$7.16, the closing price of the Common Stock as of December 31, 2009. The amounts presented for each named executive officer equal the total number of unvested awards that accelerate upon the termination of employment times the value of each award. Stock option value is \$7.16 minus the specified exercise price of the option.
- (2) The value of health and welfare benefits is estimated based upon current premiums payable with respect to insurance coverage for each named executive officer as of December 31, 2009.
- (3) Estimates based upon the maximum allowable contribution per the terms of the employment agreements and the Ameris Bancorp 401(k) Profit Sharing Plan.
- (4) Requires a relocation of within 500 miles to occur within 180 days of the date of termination. Estimates based upon reasonable moving and related expenses.
- (5) Per the terms of the employment agreements, the Company shall reduce or eliminate the payments by first reducing or eliminating those payments or benefits which are not payable in cash and then by reducing or



**Table of Contents**

eliminating cash payments, in each case in reverse order beginning with payments or benefits which are to be paid the farthest in time from the determination of benefit. As of December 31, 2009, only Mr. Hortman would be impacted by this limitation on benefit payout, with a reduction of \$340,214 in the estimated payments.

- (6) TARP regulations prohibit any golden parachute payment to an CEO and any of the next five most-highly compensated employees during the TARP period. This limitation includes any payment due to a change in control of the TARP recipient and any acceleration of vesting due to the departure or the change-in-control event. The payment would be considered paid at the time of the occurrence of the departure or the change-in-control event and, therefore, may apply to amounts for which the right to payment falls outside of the TARP period.

On December 31, 2009, C. Johnson Hipp, III voluntarily retired from the Company. Upon termination of employment, Mr. Hipp received all earned base salary compensation and vested benefits under the Company's 401(k) plan. No additional compensation was provided in connection with his retirement and termination of employment.

**Table of Contents**

**REPORT OF THE AUDIT COMMITTEE OF THE BOARD**

The Board has established a separately-designated standing Audit Committee and adopted an Amended and Restated Audit Committee Charter. The Audit Committee is comprised solely of independent directors, as defined by the listing standards of Nasdaq. The Board has determined that Mr. Sheldon is an audit committee financial expert, as defined by the rules of the SEC. The primary purpose of the Audit Committee is to assist the Board in its general oversight of the Company's financial reporting, internal controls and audit functions.

As more fully described in its charter, the Audit Committee reviews the Company's financial reporting process on behalf of the Board. The Company's management has the primary responsibility for the financial statements and the reporting process, and Porter Keadle Moore, LLP (Porter Keadle Moore), the Company's independent auditor, is responsible for performing an audit in accordance with generally accepted auditing standards to obtain reasonable assurance that the Company's consolidated financial statements are free from material misstatement and for expressing an opinion on the conformity of the financial statements with generally accepted accounting principles. The Company's internal auditors are responsible to the Audit Committee and the Board for testing the integrity of the financial accounting and reporting control systems and such other matters as the Audit Committee and Board determine.

The Audit Committee has met concerning, and has held discussions and reviewed with management, the Company's internal auditors and Porter Keadle Moore, the consolidated financial statements for the fiscal year ended December 31, 2009. Management has represented to the Audit Committee that the Company's consolidated financial statements were prepared in accordance with generally accepted accounting principles, and the Audit Committee discussed with Porter Keadle Moore the matters required to be discussed by Statement on Auditing Standards No. 61 (Communication with Audit Committees), as amended and adopted by the Public Company Accounting Oversight Board.

In addition, the Audit Committee received the written disclosures and the letter from Porter Keadle Moore required by the applicable requirements of the Public Company Accounting Oversight Board regarding Porter Keadle Moore's communications with the Audit Committee concerning independence, and has discussed with Porter Keadle Moore its independence from the Company.

Based on the review and discussions referred to above, the Audit Committee recommended to the Board that the audited financial statements be included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 for filing with the SEC.

Submitted by the Audit Committee:

J. Raymond Fulp

Robert P. Lynch

Brooks Sheldon (Chairman)

Jimmy D. Veal

V. Wayne Williford





---

**Table of Contents**

**PROPOSAL 2 RATIFICATION OF APPOINTMENT  
OF INDEPENDENT AUDITOR**

The Company has appointed Porter Keadle Moore as its independent auditor for the current fiscal year, which ends December 31, 2010. Shareholders are being asked to ratify such appointment at the Annual Meeting. In view of the difficulty and expense involved in changing auditors on short notice, should the shareholders not ratify the selection of Porter Keadle Moore, it is contemplated that the appointment of Porter Keadle Moore for the year ending December 31, 2010 will stand unless the Board finds other compelling reasons for making a change. Disapproval by the shareholders will be considered a recommendation that the Board select other auditors for the following year.

Representatives of Porter Keadle Moore (our independent auditor for the current year as well as for the most recently completed year) are expected to be present at the Annual Meeting, will have the opportunity to make a statement if they desire to do so and will be available to respond to appropriate questions by shareholders.

**Changes in Certifying Accountant**

In 2008, the Audit Committee of the Board conducted a selection process related to the Company's independent auditor. On August 28, 2008, the Company selected Porter Keadle Moore to serve as its independent auditor beginning with fiscal year 2008 and dismissed Mauldin & Jenkins, Certified Public Accountants, LLC ( Mauldin & Jenkins ) as its auditor. The Company's Audit Committee and the Board participated in and approved the decision to change the Company's independent auditor.

Mauldin & Jenkins' audit reports on the consolidated financial statements of the Company and its subsidiaries as of and for the fiscal years ended December 31, 2007 and 2006 did not contain any adverse opinion or disclaimer of opinion nor were they qualified or modified as to uncertainty, audit scope or accounting principles. In connection with Mauldin & Jenkins' audits for the two fiscal years ended December 31, 2007 and 2006 and the subsequent interim period through August 28, 2008, there were no disagreements with Mauldin & Jenkins on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Mauldin & Jenkins, would have caused it to make reference to the subject matter of the disagreements in connection with its audit reports on the financial statements for such years. Additionally, during the two fiscal years ended December 31, 2007 and 2006 and through August 28, 2008, there were no reportable events, as such term is defined in Item 304(a)(1)(v) of Regulation S-K.

During the two fiscal years ended December 31, 2007 and 2006 and the subsequent period prior to engaging Porter Keadle Moore, the Company did not consult with Porter Keadle Moore regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided to the Company that Porter Keadle Moore concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of either a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K or the related instructions thereto) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).

**Table of Contents**

**Fees and Services**

The following is a summary of the fees billed to the Company by Porter Keadle Moore for professional services rendered for the fiscal years ended December 31, 2009 and December 31, 2008:

<u>Fee Category</u>	<u>Fiscal 2009 Fees</u>	<u>Fiscal 2008 Fees</u>
Audit Fees(1)	\$ 447,945	\$ 358,661
Audit-related Fees(2)		
Tax Fees(3)		
All Other Fees(4)		
<b>Total Fees</b>	<b>\$ 447,945</b>	<b>\$ 358,661</b>

- (1) Consists of fees billed for professional services rendered for the audit of the Company's annual consolidated financial statements, review of the interim consolidated financial statements included in quarterly reports, attestation services related to management's assertions related to internal controls and services that are normally provided by such accountants in connection with statutory and regulatory filings or engagements.
- (2) Consists of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of the Company's consolidated financial statements and are not reported under Audit Fees. These services include employee benefit plan audits, consultations concerning financial accounting and reporting standards and assistance with SEC inquiries.
- (3) Consists of fees billed for professional services for tax compliance, tax advice and tax planning. These services include assistance regarding federal, state and local tax compliance and assistance with tax notices.
- (4) Consists of fees for products and services other than the services reported above. There were no fees paid to such accountants in fiscal 2009 or 2008 that are not included in the above classifications.

Additional fees were necessary in 2009 due to the Company's two FDIC-assisted acquisitions. Also, because Porter Keadle Moore was retained in August of 2008, the firm's fees for 2008 were not representative of recurring annual fees.

**Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services**

All services provided by Porter Keadle Moore are subject to pre-approval by the Audit Committee. The Audit Committee may authorize any member of the Audit Committee to approve services by Porter Keadle Moore in the event there is a need for such approval prior to the next full Audit Committee meeting. However, the Audit Committee must review the decisions made by such authorized member of the Audit Committee at its next scheduled meeting. Before granting any approval, the Audit Committee gives due consideration to whether approval of the proposed service will have a detrimental impact on Porter Keadle Moore's independence.

**The Board recommends that you vote FOR ratification of the appointment of Porter Keadle Moore as the independent auditor of the Company. Proxies will be voted FOR ratifying this selection unless otherwise specified.**

**Table of Contents**

**PROPOSAL 3 NON-BINDING ADVISORY**

**PROPOSAL ON EXECUTIVE COMPENSATION**

The American Recovery and Reinvestment Act of 2009 requires, among other things, all participants in TARP to permit a non-binding shareholder vote to approve the compensation of its executives. Accordingly, the Board is submitting for shareholder approval the proposal described below, commonly known as a say-on-pay proposal:

**Resolved, that the holders of the Common Stock hereby approve the compensation of the named executive officers as described in this Proxy Statement under Executive Compensation, including the Compensation Discussion and Analysis, the compensation tables and related material; provided, however, that this resolution shall not be binding on the Company and may not be construed as overruling any decision by the Board or the Compensation Committee.**

The Company believes that its executive compensation policies and procedures are competitive, focused on pay-for-performance principles and strongly aligned with the long-term interests of the Company's shareholders. The Company also believes that the compensation of our named executive officers for 2009 reflected the Company's financial results for 2009. In evaluating this say-on-pay proposal, the Board asks the shareholders to consider that:

the named executive officers did not receive any regular base salary increases in 2008 or 2009;

the Company did not pay any cash bonuses to the named executive officers in any of 2007, 2008 or 2009; and

the Company's executive compensation program strongly links pay with performance results and both supports our pay-for-performance culture and aligns the interests of our executives with those of our shareholders.

The vote by the shareholders will be a non-binding, advisory vote. The voting results will not be binding on the Board or the Compensation Committee or overrule or affect any previous action or decision by the Board or the Compensation Committee or any compensation previously paid or awarded. However, the Board and the Compensation Committee will take the voting results into account when they determine executive compensation decisions in the future.

**The Board recommends that you vote FOR the approval of the compensation of the named executive officers as set forth in this Proxy Statement under Executive Compensation, including the Compensation Discussion and Analysis, the compensation tables and related material. Proxies will be voted FOR the approval of the named executive officers' compensation unless otherwise specified.**

**Table of Contents****SECURITY OWNERSHIP OF CERTAIN****BENEFICIAL OWNERS AND MANAGEMENT**

The following table sets forth certain information with respect to the beneficial ownership of Common Stock, as of the Record Date, by (i) directors, (ii) nominees for election as directors, (iii) named executive officers, (iv) certain other executive officers of the Company, (v) all directors and executive officers as a group, and (vi) each person who, to the knowledge of the Company, is a beneficial owner of more than 5% of the outstanding Common Stock.

<u>Name of Beneficial Owner(1)</u>	<u>Common Stock Beneficially Owned as of March 16, 2010(2)<sup>+</sup></u>	<u>Percent of Class(3)</u>
Polaris Capital Management, Inc. 125 Summer Street Suite 1470 Boston, Massachusetts 02110	1,296,510	9.40
Dimensional Fund Advisors, Inc. Palisades West 6300 Bee Cave Road, Building One Austin, Texas 78746	866,681	6.29
BlackRock, Inc. 40 East 52nd Street New York, New York 10022	775,222	5.62
Marc J. Bogan(4)	26,004	*
Andrew B. Cheney(5)	29,726	*
Jon S. Edwards(6)	44,499	*
J. Raymond Fulp	16,422	*
Edwin W. Hortman, Jr.(7)	147,665	1.07
Daniel B. Jeter(8)	25,002	*
Cindi H. Lewis(9)	57,423	*
Robert P. Lynch(10)	83,544	*
Charles A. Robinson(11)	39,257	*
Brooks Sheldon	62,151	*
Jimmy D. Veal(12)	72,928	*
Gregory H. Walls(13)	4,712	*
V. Wayne Williford(14)	39,620	*
Dennis J. Zember Jr.(15)	110,200	*
All directors and executive officers as a group (14 persons)(16)	759,153	5.49%

\* Less than 1%.

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

+ All fractional shares have been rounded up to the next whole number.

- (1) Unless otherwise noted in this table or the footnotes to this table, the address of each beneficial owner is 310 First Street, S.E., Moultrie, Georgia 31768.
- (2) Except as otherwise specified, each individual has sole and direct beneficial voting and investment power (Rule 13d-3a) with respect to all shares of Common Stock indicated.
- (3) Percentage calculated based on 13,820,817 shares of Common Stock outstanding as of the Record Date.
- (4) Include 9,139 shares of Common Stock issuable pursuant to options exercisable within 60 days of the Record Date and 15,200 shares of restricted Common Stock over which Mr. Bogan exercises voting but not investment power.
- (5) Includes 2,031 shares of Common Stock issuable pursuant to options exercisable within 60 days of the Record Date and 27,500 shares of restricted Common Stock over which Mr. Cheney exercises voting but not investment power.

---

**Table of Contents**

- (6) Includes 20,187 shares of Common Stock issuable pursuant to options exercisable within 60 days of the Record Date, 12,250 shares of restricted Common Stock over which Mr. Edwards exercises voting but not investment power and 12 shares of Common Stock owned by Mr. Edwards wife, with whom he shares voting and investment power.
- (7) Includes 40,008 shares of Common Stock issuable pursuant to options exercisable within 60 days of the Record Date and 48,500 shares of restricted Common Stock over which Mr. Hortman exercises voting but not investment power.
- (8) Includes 5,330 shares of Common Stock owned by a Family Trust and 506 shares of Common Stock owned jointly with Mr. Jeter's brother.
- (9) Includes 21,934 shares of Common Stock issuable pursuant to options exercisable within 60 days of the Record Date; 14,500 shares of restricted Common Stock over which Mrs. Lewis exercises voting but not investment power; 1,215 shares of Common Stock owned jointly with Mrs. Lewis's husband; 58 shares of Common Stock owned jointly with Mrs. Lewis's daughter; and 668 shares of Common Stock owned by Mrs. Lewis's husband, with whom Mrs. Lewis shares voting and investment power.
- (10) Includes 1,645 shares of Common Stock owned by Mr. Lynch's wife, with whom Mr. Lynch shares voting and investment power.
- (11) Includes 9,748 shares of Common Stock issuable pursuant to options exercisable within 60 days of the Record Date and 1,114 shares owned by Mr. Robinson's wife, with whom Mr. Robinson shares voting and investment power.
- (12) Includes 25,869 shares of Common Stock owned jointly with Mr. Veal's wife and 6,877 shares of Common Stock owned by Mr. Veal's wife, with whom he shares voting and investment power.
- (13) Includes 2,600 shares of Common Stock pursuant to options exercisable within 60 days of the Record Date and 1,000 shares of restricted Common Stock over which Mr. Walls exercises voting but not investment power.
- (14) Includes 9,334 shares of Common Stock owned by Mr. Williford's wife, with whom Mr. Williford shares voting and investment power.
- (15) Includes 23,051 shares of Common Stock issuable pursuant to options exercisable within 60 days of the Record Date, 26,800 shares of restricted Common Stock over which Mr. Zember exercises voting but not investment power and 2,054 shares of Common Stock owned by Mr. Zember's children and with respect to which he has voting and investment power.
- (16) Includes 128,698 shares of Common Stock issuable pursuant to options exercisable within 60 days of the Record Date and 145,750 shares of restricted Common Stock, over which certain members of the group exercise voting but not investment power.

**SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE**

Section 16(a) of the Exchange Act requires the Company's directors, executive officers and persons who own more than 10% of the Common Stock to file with the SEC initial reports of ownership and reports of changes in ownership of the Common Stock. They are also required to furnish the Company with copies of all Section 16(a) forms they file with the SEC.

To the Company's knowledge, based solely on its review of the copies of such reports furnished to it and written representations that no other reports were required, during the fiscal year ended December 31, 2009, all of the Company's officers, directors and greater than 10% shareholders complied with all applicable Section 16(a) filing requirements, except for Mr. Veal, who did not timely complete two required Form 4 filings relating to an aggregate of three transactions.

**Table of Contents**

**CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS**

The Company and the Bank have engaged in, and in the future expect to engage in, banking transactions in the ordinary course of business with directors and officers of the Company and the Bank and their family members and associates, including corporations, partnerships and other organizations in which such directors and officers have an interest. The Company and the Audit Committee review all relationships and transactions in which the Company and such related persons are participants, including such banking transactions, on a case-by-case basis. In performing such review, consideration is given to (i) the nature of the related person's interest in the transaction, (ii) the material terms of the transaction, (iii) the significance of the transaction to the related person or the Company, and (iv) other matters deemed appropriate. Company policy prohibits the making of loans to executive officers.

At December 31, 2009, certain employees and directors and their affiliates were indebted to the Bank in the aggregate amount of approximately \$8 million. These loans were made in the ordinary course of business, on substantially the same terms (including interest rates, collateral and repayment terms) as those prevailing at the time for comparable transactions with others not related to the Company or the Bank and, in the opinion of management, do not involve more than the normal risk of collectibility or present other unfavorable features.

**OTHER MATTERS**

The Board does not contemplate bringing before the Annual Meeting any matter other than those specified in the accompanying Notice of Annual Meeting of Shareholders, nor does it have information that other matters will be presented at the Annual Meeting. If other matters come before the Annual Meeting, signed proxies will be voted upon such questions in accordance with the best judgment of the persons acting under the proxies.

**ADDITIONAL INFORMATION**

**Shareholder Proposals**

Any shareholder proposal intended to be presented at the Company's annual meeting of shareholders to be held in 2011 and to be included in the Company's proxy statement and form of proxy for that meeting must be in writing and must be received by the Company, directed to the attention of the Corporate Secretary, not later than November 22, 2010. Any such proposal must comply in all respects with the rules and regulations of the SEC.

**Annual Report**

A copy of the Company's Annual Report to Shareholders is enclosed with this Proxy Statement. The Annual Report to Shareholders is not deemed a part of the proxy soliciting material. The Company's Annual Report to the SEC on Form 10-K for the fiscal year ended December 31, 2009 was filed with the SEC on March 16, 2010. Upon receipt of a written request, we will, without charge, furnish any owner of our Common Stock a copy of the Annual Report on Form 10-K, including financial statements and the footnotes thereto. Copies of exhibits to the Annual

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

Report on Form 10-K are also available upon specific request and payment of a reasonable charge for reproduction. Such request should be directed to our Corporate Secretary at the address indicated on the first page of this Proxy Statement.



**Table of Contents**

**Householding of Proxy Materials**

The SEC has adopted rules that permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements with respect to two or more shareholders sharing the same address by delivering a single proxy statement addressed to those shareholders. This process, which is commonly referred to as householding, potentially provides extra convenience for shareholders and cost savings for companies. A number of brokers with account holders who are shareholders of the Company will be householding the Company's proxy materials. Once you have received notice from your broker that it will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement, or if you are receiving multiple copies of the proxy statement and wish to receive only one, please notify your broker or notify us by sending a written request to Ameris Bancorp, 310 First Street, S.E., Moultrie, Georgia, 31768, Attn: Corporate Secretary, or by calling 229-890-1111.

**Table of Contents**

*Appendix A*

**AMERIS BANCORP**

**AMENDED AND RESTATED AUDIT COMMITTEE CHARTER**

**I. Purpose**

The primary function of the audit committee (the *Audit Committee*) of the Board of Directors (the *Board*) of Ameris Bancorp (the *Corporation*) is to assist the Board in fulfilling its oversight responsibilities relating to the accounting, legal and reporting practices of the Corporation. The Audit Committee shall provide assistance to the directors in fulfilling their responsibility to the shareholders of the Corporation, relating to corporate accounting, reporting practices of the Corporation and the quality and integrity of the financial reports of the Corporation. In so doing, it is the responsibility of the Audit Committee to maintain free and open communication between the directors, the Corporation's independent auditors, the Corporation's internal auditors, if any, or the entity performing the internal audit function, and the financial management of the Corporation.

Consistent with this function, the Audit Committee should encourage continuous improvement of, and should foster adherence to, the Corporation's policies, procedures and practices. The Audit Committee will primarily fulfill these responsibilities by carrying out the activities enumerated in Section IV of this Charter.

**II. Composition**

The Audit Committee shall be comprised of three or more directors as determined by the Board, each of whom shall be independent directors and free from any relationship that, in the opinion of the Board, would interfere with the exercise of his or her independent judgment as a member of the Audit Committee. All members of the Audit Committee shall meet the independence, experience and expertise requirements of the National Association of Securities Dealers, Inc. (the *NASD*), the Sarbanes-Oxley Act of 2002 and applicable rules and regulations of the Securities and Exchange Commission (the *SEC*). At all times at least one member of the Audit Committee shall be an audit committee financial expert within the meaning of Section 407 of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations of the SEC. The Board shall elect members of the Audit Committee each year at a regular or special meeting of the Board or until their successors shall be duly elected and qualified. Unless the full Board elects a Chairman, the members of the Audit Committee may designate a Chairman by majority vote of the full Audit Committee membership.

**III. Meetings**

Regular meetings of the Audit Committee may be held without notice at such time and at such place as shall from time to time be determined by the Chairman of the Audit Committee, the President or the Secretary of the Corporation. Special meetings of the Audit Committee may be called by or at the request of any member of the Audit Committee, any of the Corporation's executive officers, the Secretary, the director of

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

Corporation's internal auditing department, if any, or the Corporation's independent auditors, in each case on at least twenty-four hours notice to each member.

If the Board, management, the director of Corporation's internal auditing department, if any, or the Corporation's independent auditors desire to discuss matters in private, the Audit Committee shall meet in private with such person or group.

A majority of the Audit Committee members shall constitute a quorum for the transaction of the Audit Committee's business. Unless otherwise required by applicable law, the Corporation's Articles of Incorporation or Bylaws or the Board, the Audit Committee shall act upon the vote or consent of a majority of its members at a

A-1

## **Table of Contents**

duly called meeting at which a quorum is present. Any action of the Audit Committee may be taken by a written instrument signed by all of the members of the Audit Committee. Meetings of the Audit Committee may be held at such place or places as the Audit Committee shall determine or as may be specified or fixed in the respective notices or waivers of meetings. Members of the Audit Committee may participate in Audit Committee proceedings by means of conference telephone or similar communications equipment by means of which all persons participating in the proceedings can hear each other, and such participation shall constitute presence in person at such proceedings

As part of its job to foster open communication, the Audit Committee should meet at least annually with management, the director of the Corporation's internal auditing department, if any, and the Corporation's independent accountants in separate executive sessions to discuss any matters that the Audit Committee or each of these groups believe should be discussed privately.

### **IV. Responsibilities and Duties**

To fulfill its responsibilities and duties, the Audit Committee shall:

1. Be directly responsible for the selection, appointment, compensation, oversight and, where appropriate, authorization of the replacement of the auditors. The Audit Committee shall determine compensation for the auditors on an annual basis and approve, in advance, all audit services to be performed by the auditors. The Audit Committee will review the auditors' report covering all matters required by applicable SEC and NASD regulations, including the auditors' internal quality control procedures and the experience and qualifications of the senior members of the auditor team.
2. Confirm the independence of the auditors, including, by way of example: (i) approving, in advance, the retention or selection of the auditors for any permissible non-audit services provided by the auditors, such as tax services, in accordance with applicable SEC and NASD regulations, and the fees relating thereto; (ii) obtaining, at least annually, a formal written statement from the auditors confirming their independence from the Corporation and delineating relationships between the auditors and the Corporation, including past employment by the auditors of Corporation personnel, that might have an impact on their independence; and (iii) actively engaging in dialogue with the auditors regarding matters that might reasonably be expected to affect their objectivity and independence. The Audit Committee may delegate pre-approval authority to a member of the Audit Committee. The decisions of any Audit Committee member to whom pre-approval authority is delegated must be presented to the full Audit Committee at its next scheduled meeting.
3. Oversee the Corporation's compliance with the requirements of all applicable laws and SEC and NASD regulations, and any amendments thereto, including procedures for the rotation of audit partners, and guidelines for the Corporation's hiring of employees of the audit firm who were engaged in the Corporation's account.
4. Meet with the auditors and financial management of the Corporation to review the scope and cost of the proposed audit for the current year and the audit procedures to be utilized and, following the conclusion thereof, review the results of such audit, including any comments or recommendations of the auditors. Such review should also include any management letter provided by the auditors and the Corporation's response letter, if any.
5. Review with the auditors and the Corporation's financial management and accounting personnel the adequacy, reliability and integrity of the accounting policies, internal controls and financial reporting controls of the Corporation.

## Edgar Filing: Symmetry Medical Inc. - Form 10-K

6. Review reports prepared for the Audit Committee by management and/or the auditors of significant reporting issues and judgments made in connection with the preparation of the Corporation's financial statements, including an analysis of critical accounting policies and the effect of alternative GAAP methods on

A-2

**Table of Contents**

the Corporation's financial statements, and review with the auditors and Corporation's financial management and accounting personnel the potential effect of regulatory and accounting developments on the Corporation's financial statements.

7. Review and approve, in advance, all related party transactions in accordance with applicable law and SEC and NASD regulations.

8. Assist the Corporation's management in the establishment and maintenance of disclosure controls and procedures in accordance with applicable law and SEC and NASD regulations that are adequate to meet the Corporation's reporting obligations under applicable securities laws.

9. Establish and maintain procedures for the receipt, retention and treatment of complaints received by the Corporation with respect to accounting, internal accounting controls or auditing matters which shall include procedures for the confidential and anonymous treatment of submission of such complaints by employees. Review with management and the auditors any correspondence with regulators or government agencies and any employee complaints or published reports which raise material issues regarding the Corporation's financial statements or accounting policies.

10. Review with the Corporation's legal counsel or other appropriate legal personnel any legal matters that may have a material impact on the Corporation's financial statements, the Corporation's compliance policies, business conduct controls and any material reports or inquiries received from regulators or governmental agencies.

11. Meet with the auditors in executive session at least once per quarter. The Audit Committee will review with the auditors any problems or difficulties encountered during the audit and management's response, and undertake the responsibility to investigate and resolve any disagreements between the Corporation's management and the auditors regarding the Corporation's financial reporting or in the course of the audit work.

12. Review with the auditors and the Corporation's financial management and accounting personnel the Corporation's proposed earnings releases and financial guidance, if any, and quarterly financial statements, including any review by the auditors of the quarterly financial statements, prior to the filing of the Corporation's Quarterly Report on Form 10-Q. Such review shall include, without limitation, a discussion of Management's Discussion and Analysis of Operations proposed to be set forth in the Quarterly Report on Form 10-Q and of all matters necessary for the certifications of such report by the Corporation's management in accordance with applicable law.

13. Discuss with the auditors the results of the annual audit of the Corporation's financial statements, including (i) the auditors' assessment of the quality, not just acceptability, of accounting principles, (ii) the reasonableness of significant judgments, (iii) the nature of significant risks and exposures, (iv) the adequacy of the disclosures in the financial statements and (v) any other matters required to be communicated to the Audit Committee by the auditors under auditing standards generally accepted in the United States. The Audit Committee shall review with the auditors and the Corporation's financial management and accounting personnel the Corporation's annual financial statements prior to the filing of its Annual Report on Form 10-K and management's assertions related to its assessment of the effectiveness of internal controls as of end of the most recent fiscal year and, as required, the auditors' report on such assertions. The discussion of the financial statements shall include, without limitation, a discussion of Management's Discussion and Analysis of Operations proposed to be set forth in the Annual Report on Form 10-K and of all matters necessary for the certifications of such report by the Corporation's management in accordance with applicable law.

Edgar Filing: Symmetry Medical Inc. - Form 10-K

14. Review and discuss with management and the auditors any material financial or non-financial arrangements of the Corporation which do not appear in the Corporation's financial statements and any

A-3

**Table of Contents**

transactions or arrangements with parties related to the Corporation which transactions are significant in size or involve terms or other aspects that differ from those that would likely be negotiated with independent parties, and which arrangements or transactions are relevant to an understanding of the Corporation's financial statements.

15. Investigate matters brought to its attention within the scope of its duties. In discharging these responsibilities, the Audit Committee will have full access to the Corporation's books and records, and will have the power to retain outside counsel or other advisors to assist the Audit Committee for this purpose, and to determine the compensation for any such advisors.

16. Hold such regular meetings as may be necessary and such special meetings as may be called by the Chairman of the Audit Committee or at the request of the auditors; prepare the minutes from such meetings and submit them to the Board.

17. Prepare a report to be included in the Corporation's annual proxy statement as required by applicable SEC and NASD regulations.

18. Review and reassess the adequacy of the Audit Committee Charter on an annual basis.

19. Perform such other functions and have such powers as may be necessary or appropriate in the efficient and lawful discharge of the foregoing.

**V. Miscellaneous**

The Audit Committee may perform any other activities consistent with this Charter, the Corporation's Articles of Incorporation and bylaws and governing law, as the Audit Committee or the Board deems necessary or appropriate.

\* \* \* \* \*

*Approved by the Ameris Bancorp Board of Directors on February 17, 2004.*

A-4



**Table of Contents**





## Fiscal Year 2010 Compared to Fiscal Year 2009

Revenue. Revenue for fiscal 2010 decreased \$5.1 million or 1.4% to \$360.8 million from \$365.9 million in fiscal 2009. Revenue for each of our principal product categories in these periods was as follows:

	Product Category	
	2010	2009
	(in millions)	
Instruments	\$ 145.4	\$ 166.7
Implants	111.3	108.0
Cases	81.7	68.5
Other	22.4	22.7
Total	\$ 360.8	\$ 365.9

The \$5.1 million decrease in revenue resulted from unfavorable foreign currency exchange rate fluctuations of \$2.4 million as well as a \$2.7 million reduction in overall customer demand. Our customer demand reached a recent low level in the fourth quarter of 2009, then increased throughout 2010. Instrument revenue decreased \$21.3 million in fiscal 2010, driven primarily by lower demand from our five largest OEM customers of \$27.8 million due to the timing of their various product launches. After a strong first half of 2009, instrument demand decreased during the second half of 2009. Demand improved in 2010 as compared to the second half of 2009, but not sufficiently to offset the decrease experienced during the first half of 2010 as compared to the strong first half of 2009. We did experience growth of \$6.5 million from other customers during fiscal 2010 as compared to fiscal 2009 driven by our efforts to diversify our customer base in both orthopedic and non-orthopedic markets. Implant revenue increased \$3.3 million in fiscal 2010 which was driven by increased customer demand of \$4.8 million, primarily from our five largest OEM customers, to support procedure growth, offset by unfavorable foreign currency exchange rate fluctuations of \$1.5 million. Case revenues increased \$13.2 million in fiscal 2010 as compared to 2009 due primarily to an increase in customer demand from our five largest OEM customers due to the timing of their various product launches. This increased demand was partially offset by \$0.7 million of unfavorable foreign currency exchange rate fluctuations in case revenues. Other product revenue decreased \$0.3 million, primarily attributable to unfavorable foreign currency exchange rate fluctuations of \$0.2 million.

Gross Profit. Gross profit for fiscal 2010 decreased \$7.3 million, or 8.4%, to \$79.7 million from \$87.0 million in fiscal 2009 due to decreased gross profit as a percentage of revenue and decreased revenue of 1.4%. The Corporation's gross profit as a percentage of revenue was 22.1% in 2010 a decline from 23.8% in 2009. This decrease was primarily due to manufacturing inefficiencies resulting from our facility consolidation efforts in 2010 and unfavorable changes in product mix resulting in higher material cost as a percentage of revenue. Despite increased costs for resources to support higher customer and FDA regulatory expectations, labor and overhead costs remained relatively consistent as a percentage of revenue as we endeavored to match variable costs in line with the volatility in customer ordering patterns. Changes in foreign currency exchange rates negatively affected our total year 2010 gross profit by \$0.4 million.

Selling, General and Administrative Expenses. Selling, general and administrative expenses in fiscal 2010 increased \$2.7 million, or 5.6%, to \$50.5 million from \$47.9 million in fiscal 2009. This increase was primarily driven by strategic investment in research and development expenditures, increased marketing expenditures as well as increased sales commissions and healthcare costs. These increases were partially offset by \$1.6 million reduction in non-cash stock related compensation expense. As a percentage of revenue, selling, general and administrative expenses were 14.0% in fiscal 2010 as compared to 13.1% in fiscal 2009. Changes in foreign currency exchange rates increased our selling, general and administrative expenses by \$0.1 million.

Facility Consolidation and Severance Costs. Results of Operations for fiscal 2010 include charges of \$1.0 million associated with employee cost reduction and efficiency actions as well as current period costs associated with the consolidation of our Auburn, Maine facility. These costs are comprised of \$0.6 million of severance costs and an additional \$0.4 million of asset impairment and moving expenses. The 2009 results of operations include net charges of \$2.8 million related primarily to the consolidation of our Whitman, Massachusetts and Auburn, Maine facilities into other facilities that produce similar products. These costs are comprised of \$1.4 million of severance costs and an additional \$1.4 million of asset impairment and moving expenses. As of January 1, 2011, all charges had been paid. As of January 2, 2010, severance accruals related to these cost reduction and efficiency actions totaled \$0.8 million, and were included in accrued and other liabilities in the consolidated balance sheets.

Other (Income) Expense. Interest expense for fiscal 2010 decreased \$0.9 million, or 14.3%, to \$5.7 million from \$6.6 million in fiscal 2009. During 2010, we refinanced substantially all of our debt arrangements that were to mature in June 2011, which resulted in a loss on debt extinguishment of \$0.8 million. In 2009, we entered into a forward swap contract to manage interest rate risk related to a portion of our current outstanding term loan indebtedness due in 2011. This swap contract was designated as a cash flow hedge of the future payment of variable rate interest with three-month LIBOR fixed at 1.34% per annum in 2009, 2010 and 2011. The net derivatives valuation gain for 2010 consists of a gain on interest rate swap valuation of \$1.3 million related to our interest rate swap that was not designated as a hedge as compared to a gain of \$1.2 million in fiscal 2009. As part of our debt refinancing that occurred in November 2010, both these interest rate swaps were settled.

Provision for Income Taxes. Our effective tax rate in fiscal year 2010 was 36.2% compared to 28.4% in fiscal 2009. The 2010 effective tax rate approximates the U.S. Federal statutory rate of 35% and has increased over fiscal 2009 primarily due to reduced benefits from the favorable impacts of income generated in foreign jurisdictions with lower statutory tax rates.

#### Fiscal Year 2009 Compared to Fiscal Year 2008

Revenue. Revenue for fiscal 2009 decreased \$57.5 million or 13.6% to \$365.9 million from \$423.4 million in fiscal 2008. Revenue for each of our principal product categories in these periods was as follows:

	Product Category	
	2009	2008
	(in millions)	
Instruments	\$ 166.7	\$ 177.5
Implants	108.0	122.6
Cases	68.5	86.4
Other	22.7	36.9
Total	\$ 365.9	\$ 423.4

The \$57.5 million decrease in revenue resulted from unfavorable foreign currency exchange rate fluctuations of \$13.6 million as well as challenging business conditions in the second half of 2009 due to the overall economic environment that has resulted in reduced demand of 10.4% for our five largest OEM customers as they continue to work down inventory levels and adjust the timing of their various product launches. Instrument revenue decreased \$10.8 million. This decrease was driven primarily by lower demand from our major OEM customers due to the timing of their various product launch activity and their reduction of inventory levels. Foreign currency exchange rate fluctuations had an unfavorable impact of \$1.7 million on instrument revenue, however, this was more than offset by \$2.2 million of incremental instrument revenue from our New Bedford acquisition which was completed at the end of January 2008. Implant revenue decreased \$14.6 million in fiscal 2009 which was driven by unfavorable foreign currency exchange rate fluctuations of \$7.0 million and decreased customer demand of \$8.1 million as our major OEM customers worked down their inventory levels. This was partially offset by the additional sales from our New Bedford acquisition of \$0.5 million. Case revenues decreased \$17.9 million for fiscal 2009 mainly due to a \$16.5 million decrease in customer demand primarily from our non-orthopedic medical customers as they react to the current economic environment. Additionally, we experienced a reduction in demand from our five largest OEM customers as they work down inventory levels and adjust the timing of product launches combined with \$1.4 million unfavorable foreign currency exchange rate fluctuations in case revenues. Other product revenue decreased \$14.2 million driven by both a reduction in customer demand of \$10.7 million due to our largest customer in the aerospace industry reacting to economic market conditions in that sector and unfavorable foreign currency exchange rate fluctuations of \$3.5 million.

We estimate that global orthopedic device procedures grew approximately 4% in 2010 compared to 6% in 2009 and we expect slightly higher industry procedure growth in the future.

Gross Profit. Gross profit for fiscal 2009 decreased \$13.3 million, or 13.3%, to \$87.0 million from \$100.3 million in fiscal 2008 primarily due to the decline in revenue of 13.6%. Despite experiencing declining revenues, the Corporation was able to increase the gross profit as a percentage of revenue to 23.8% in 2009 from 23.7% in 2008. This improvement was primarily due to aggressive actions to manage labor and other costs at all facilities and improved operational performance at our Sheffield, UK operating unit driven by the continued favorable impacts of our new ERP system, implemented in March 2009, headcount reductions, improved manufacturing processes and reduced material costs from the renegotiation of a key supply agreement. We continue to drive improvements at

Sheffield and anticipate continued improvements in the future. Changes in foreign currency exchange rates negatively affected our total year 2009 gross profit by \$1.1 million.

**Selling, General and Administrative Expenses.** Selling, general and administrative expenses in fiscal 2009 decreased \$10.4 million, or 18.0%, to \$47.9 million from \$58.3 million in fiscal 2008. This decrease was primarily driven by a \$5.6 million decrease in employee compensation costs, including reductions in headcount due to decreased production, reduced overtime costs and decreased performance based compensation and non-cash stock compensation expense due to lower financial results. The improvement also reflects a reduction in professional fees and expenses incurred during 2008 of \$4.7 million from the review of accounting irregularities at our Sheffield, UK operating unit. As a percentage of revenue, selling, general and administrative expenses were 13.1% in fiscal 2009 as compared to 13.8% in fiscal 2008. Changes in foreign currency exchange rates decreased our selling, general and administrative expenses by \$0.9 million.

Facility Consolidation and Severance Costs. Results of Operations for fiscal 2009 include net pre-tax charges of \$2.8 million related primarily to the consolidation of our Whitman, Massachusetts and Auburn, Maine facilities into other facilities that produce similar products. These costs are comprised of \$1.4 million of severance costs and an additional \$1.4 million of asset impairment and moving expenses. As of January 2, 2010, severance accruals related to these cost reduction and efficiency actions totaled \$0.8 million, and are included in accrued and other liabilities in the consolidated balance sheets. This accrual is expected to be paid during the first quarter of 2010.

Other (Income) Expense. Interest expense for fiscal 2009 decreased \$3.5 million, or 34.1%, to \$6.6 million from \$10.1 million in fiscal 2008. This decrease reflects the reduction in our interest rate margin above LIBOR due to improved financial ratios, as well as the general decline in the interest rate market in 2009 as compared to 2008. Additionally, aggregate outstanding indebtedness has decreased \$35.0 million, or 26.7% as compared to January 3, 2009. In 2009, we entered into a forward swap contract to manage interest rate risk related to a portion of its current outstanding term loan indebtedness due in 2011. This swap contract is designated as a cash flow hedge of the future payment of variable rate interest with three-month LIBOR fixed at 1.34% per annum in 2009, 2010 and 2011, respectively. The net derivatives valuation gain for 2009 consists of a gain on interest rate swap valuation of \$1.2 million related to our interest rate swap that has not been designated as a hedge as compared to a loss of \$1.8 million in fiscal 2008. During 2008, we also held foreign currency forwards to mitigate fluctuations in foreign currency on the statement of operations. A gain on the foreign currency valuation of \$4.3 million was recorded in derivative valuation gain in 2008 and partially offset \$3.3 million of losses on foreign currency fluctuations that were included within other expense.

Provision for Income Taxes. Our effective tax rate in fiscal year 2009 was 28.4% compared to 23.8% in fiscal 2008. This rate is lower than the U.S. Federal statutory rate primarily due to the favorable impact of foreign income taxes as we benefited from an increase in income earned in foreign jurisdictions in 2009 where the statutory tax rate is lower than the Federal statutory rate. We also recognized \$0.5 million of valuation allowance against foreign losses incurred during the year.

## Liquidity and Capital Resources

### Liquidity

Our principal sources of liquidity in fiscal 2010 were cash generated from operations and borrowings under our revolving credit facilities. Principal uses of cash in fiscal 2010 included increased working capital and capital expenditures as well as debt service. We expect that our principal uses of cash in the future will be to finance working capital, to pay for capital expenditures, to service debt and to fund possible future acquisitions. In November 2010, we entered into a new revolving credit facility which has total borrowing capacity of up to \$200 million with an option to increase capacity, with the approval of the lenders, by \$100 million.

We believe our cash resources will permit us to stay committed to our strategic plan of increasing our share in the orthopedic market and expanding into other medical device segments. The following table summarizes our primary sources and uses of cash in the periods presented:

	2010	Fiscal Year Ended 2009	2008
		(in millions)	
Net Cash Flow provided by (used in):			
Operating activities	\$ 17.9	\$ 53.4	\$ 25.7
Investing activities	(14.0 )	(14.9 )	(68.0 )
Financing activities	(2.5 )	(35.6 )	41.5



Effect of exchange rate changes on cash and cash equivalents	(0.6 )	1.1	(1.1 )
Net increase (decrease) in cash and cash equivalents	\$ 0.8	\$ 4.0	\$ (1.9 )

Operating Activities. We generated cash from operations of \$17.9 million in fiscal 2010 compared to \$53.4 million in fiscal 2009. The decline in operating cash flows is primarily the result of working capital requirements increasing during the course of 2010 in line with revenue growth as compared to declines during the course of 2009. Working capital used \$20.0 million of cash in 2010 compared to cash generation of \$2.5 million in 2009. The decrease in cash from operations is also due to a decrease in net income from 2009 to 2010 of \$7.8 million. During 2009, the significant increase in cash from operations is primarily the result of lower working capital requirements given the reduction in revenue in the second half of 2009. As revenue declined, the Corporation focused on reducing account receivable days, reducing required inventory levels and extending accounts payable terms.